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Corrections in Canada and “Sunny Days”
For those following our 
national developments of 
late in the field, the expan-
sion of our jails and their 
perception as their being our 
largest mental institutions, 
I thought that our CJA/JCA 
should welcome articles 
reporting on the practices of 
Addiction Medicine in our 
Correctional System. As new more liberal policies are set 
to sweep the country, shining some light on our current 
system becomes even more timely.
Three recent international publications provide a 
perspective into systems which are traditionally scant 
on research. The first is a booklet from the US collating 
principles and guidelines for the delivery of psychiatric 
services in their corrections facilities.1 In 1989, this nation’s 
jails and prisons held an estimated 1.2 million men and 
women. By 2012, that number had almost doubled to 2.2 
million. Major contributors were the harsher sanctions 
created by the “war on drugs” and an attitude promot-
ing “getting tough on crime”. Does it sound familiar? 
Upward of 700 000 of these men and women had active 
serious mental disorders with 3 out of 4 of these incar-
cerated persons having a co-occurring substance use 
disorder. Physicians including Psychiatrists who prac-
tice in jails and prisons function almost exclusively as 
diagnosticians and prescribers, with little room for the 
complementary skills they possess. 
The second notable reference is a special issue of the 
Canadian Journal of Psychiatry focussing on a National 
Trajectory Project studying the 1800 individuals found 
not criminally responsible on account of mental disor-
der (NCRMD) in Canada.2 The issue highlights a lack of 
consideration for scientific evidence compared to the 
prominence of political ideology underpinning the new 
Bill C-54, in effect since July 2014. References in the issue 
to substance use disorder were few nonetheless here are 
some examples: alcohol and drug abuse were mentioned 
in 25% of cases at the time of the offense and a substance 
use disorder in 30% of cases at the time of the verdict. 
By comparison, mental status was mentioned in 70% of 
cases with delusions noted in about 50% of these cases. 
Suicidal or homicidal ideations were rare, less than 10% 
of cases.
The third reference is a needed reminder from Sweden 
that substance abuse continues to contribute to excess 
mortality in people released from prison. In a sample 
of 47326 individuals released from prison and follow up 
for a median 5 years, 6% died. Substance use disorders 
contributed significantly to the rate of all cause mortal-
ity (adjusted HR 1.6) and this rate was independent of 
sociodemographic, criminological and familial factor.3
The above references should provide context to the 
papers by Dr. Lanoie and Dr. Craig.
There are of course other major contributions in this 
issue. We welcome the first paper from the Canadian 
Centre on Substance Abuse with Dr. Young et al moni-
toring the current fentanyl epidemic through CCENDU. 
Another first is a contribution from Ireland with Dr. 
Truszkowska et al investigating mortality risk factors of 
patients on MMT. We also publish an interesting obser-
vation on the “creative” use of gift cards for research 
participation by Dr. Finch et al. Lastly, Dr. Vincent 
from Edgewood, one of our major residential programs, 
has published a handbook on diagnosing and treating 
addictions. The Journal is pleased to provide a review of 
this laudable effort.
Back to “Sunny Days”, our Journal will of course be 
pleased to report on the impact of the anticipated new 
policies. 
Nady el-Guebaly, MD 
Editor-in-Chief, CJA-JCA
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Opioid Substitution Therapy In Canada’s Prisons
Leo O. Lanoie, MD
ABSTRACT
This paper presents a synopsis of the Canadian penal 
system. It then describes the introduction and evolution 
of opioid substitution therapy (OST) across the system’s 
levels. Measures of success are reported.
Cet article présente un sommaire du système de justice 
pénale canadien suivi d’une description de l’introduction 
et l’évolution du traitement de substitution aux opiacés 
(TSO). Des mesures de succès sont rapportées.
INTRODUCTION
In 2010 a parliamentary committee reported that:
 Every year, Correctional Service of Canada (CSC) 
is responsible for slightly more than 22,000 offend-
ers, approximately 13,000 of whom are inmates at a 
correctional facility and 8,800 others who have been 
released under community supervision1
The same report goes on to state:
 In Canada, some 80% of offenders serving prison 
sentences of two years or more have problems with 
drugs and/or alcohol.
Data from the provincial and territorial prisons is not 
readily available.
THE CANADIAN PENAL SYSTEM
The Canadian penal system has three levels. The first is 
the local lock up – the police station. This is relevant to 
addiction medicine because patients on opioid substitu-
tion therapy (OST methadone/suboxone®) are picked up 
for various reasons. Response to patients’ need for medi-
cation is variable, but many police services make an effort 
to see that the detainee receives his or her methadone/
suboxone® while in lock up. Some clinics include the 
police in the “circle of care” listed on the consent form. 
That allows the physician to tell a police officer that, “yes, 
patient x is on so many mg of methadone per day and gets 
his daily dose at pharmacy Y.” Some police officers will 
simply inform the prescriber that patient x is in cells and 
to please inform the pharmacy that a constable will be by 
to pick up today’s dose. Since patients may spend several 
days in lock up it is important for prescribers to keep 
their local police service well informed of their program, 
not by naming individual patients but by educating them 
about the importance of receiving daily medication, even 
when locked up.
The next level is provincial or territorial corrections 
services. In Canada Criminal Law is Federal Law. Anyone 
convicted of an offence meriting two year or more will be 
sent to a federal penitentiary. Those are sentenced to no 
more than “two years less a day” end up in a provincial 
correctional centre. Many such centres are overcrowded. 
Convicted persons will often opt for a sentence of two 
years in order to be sent to a federal institution, where 
programs are better.
The term “programs” refer to everything from structured 
educational courses to CBT based group sessions. 
OPIOID SUBSTITUTION THERAPY
Most if not all provincial correctional services allow 
inmates who enter the system on methadone to continue 
on methadone. Suboxone® is more problematic and 
depends largely on whether or not the provincial drug 
plan funds Suboxone. ® Because of the relatively short 
stay in provincial facilities, of the difficulty in organizing 
continuity of care once released, and of the uncertainty 
as to exactly when the inmate may be released, start-
ing a patient on methadone in provincial corrections is 
problematic and policies vary from province to province. 
(Strange as it may seem release dates are not always 
known. Inmates get time off for good behaviour, time 
served for prior to sentencing, etc. Also, if the release 
date falls on the Monday of a long weekend, the inmate 
may be released the Friday before, usually at five o’clock.) 
Most provincial correctional systems do allow medically 
at risk inmates to be started on methadone if a case can 
be made that methadone is essential to the management 
Author Institution: Prince Albert Cooperative Health Centre, 
Saskatchewan Penitentiary and The Prince Albert Men’s Provincial 
Correctional Facility
Author Contact: l.lanoie@sasktel.net 
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of their medical condition. This is easy to do for an opioid 
dependent inmate whose treatment success depends on 
strict adherence to a medication regimen.
The Correctional Service of Canada (CSC) has a long 
tradition of providing and perfecting non pharmacologi-
cal care for inmates with severe substance abuse disor-
der. CSC introduced methadone maintenance in phases. 
In December 1997 CSC started maintaining offenders 
on methadone who were admitted to CSC already on 
Methadone (Phase 1). By February 1999 offenders could 
be initiated on Methadone under exceptional circum-
stances. In May, 2002 access to methadone maintenance 
became accessible to all inmates that met the criteria 
for opioid dependence (Phase 2). The National Specific 
Guidelines for Opioid Dependence were promulgated 
to insure consistency in application in all CSC institu-
tions. In 2008 the Guidelines were amended to include 
Suboxone®. By 2010 opioid substitution therapy was avail-
able in fifty one of CSCs 57 institutions.2 Six institutions 
were deemed unsuitable for OST due to perennial staff-
ing difficulties.  In institutions that have sufficient nurs-
ing staff but no access to a methadone prescribing physi-
cian, (isolated healing lodges), clinics with a methadone 
prescriber are done via videoconferencing.
Initially, MMT was not well received in many institu-
tions. CSCs response was education and supervision. A 
National Coordinator (RN) was appointed to manage the 
program as a whole.  A Regional Coordinator (RN) was 
appointed in each of the five correctional regions. The 
Regional Coordinators’ mandate was to ensure that the 
provisions of the Guidelines were applied at the institu-
tional level. This was done by site visits to observe clinical 
and dispensing practices, to review charts and to help 
the staff problem solve.  Each of the five regions had a 
Regional Medical Consultant, whose job it was to assess, 
advise and support institutional physicians in the care of 
opioid dependent inmates and to be a resource for the 
Regional Coordinator. A National Medical Consultant 
was contracted to advise the National Coordinator and to 
help educate CSC staff at all levels about addiction and its 
treatment. Training Days were held in 11 different centres 
across Canada every two years over a six year period. 
These were attended by medical, nursing, programing, 
parole and correctional (security) officers. In addition, 
attendance at CSAM conferences was facilitating for 
nursing and program staff. Institutional physicals were 
also encouraged to attend. 
The Medical Consultants and Regional Coordinator posi-
tions were phased out in 2014. This was probably due to 
budget cuts. By that time, however, (OST) was well estab-
lished and accepted in CSC and those positions were less 
acutely needed.
Any offender with opioid dependence can apply for OST. 
The application is reviewed by a committee consist-
ing of the OST nurse, the offender`s parole officer and 
program officer. The physician makes the final decision 
as to whether or not the inmate is a suitable candidate for 
OST. The other personnel continues to play a vital part in 
the inmate’s substance abuse care. The only requirement 
for OST is a diagnosis of Severe Opioid Use Disorder 
and a desire on the part of the offender to participate 
in the program. Only inmates who will be released in 
the foreseeable future and who insists on returning to 
an area where OST is not available are refused OST. In 
Institutions where there are waiting lists (at present there 
aren’t many) inmates who are due to be released within 
six months are given priority. The OST team has a respon-
sibility to assure continuity of care once the offender is 
released into the community.
The program is highly structured. Every effort is made 
to avoid diversion. The administration of methadone is 
directly observed and the 20 minute rule (observation by 
a Correctional Officer for 20 minute) is enforced. Some 
institutions even use a 30 minute rule. Urine Drug Testing 
(UDT) is once a week initially. Once the patient is stable 
(no major dose changes and negative toxicology) the 
tests are done randomly more or less every 2 weeks. Only 
health care staff has access to urine toxicology results. 
Correctional officers can demand a UDT from an offender 
at any time and these results can be used punitively; OST 
toxicology results cannot. OST patients are expected to 
participate in programs (addiction related educational 
and counselling sessions). Involuntary tapers are rare 
and are almost always due to persistent attempts to divert 
methadone to other inmates.
Suboxone® is available only for patients who cannot toler-
ate methadone. It is rarely used.
PREVALENCE OF COMORBIDITIES
As with victims of substance use disorder everywhere, 
incarcerated patient have a high prevalence of medi-
cal and psychiatric co-morbidity. HIV and Hep C are 
common and are treated by physicians expert in the 
management of those conditions. Psychiatric co-morbid-
ity is very common. In 2008 MMT participant reported 
lifetime prevalence of:3
•	 Treatment for anxiety: 48%
• Treatment for depression: 46%
• Treatment for panic disorders:23%
• Treatment for psychosis: 10%
• Treatment for any other emotional problem: 18%
• Previous psychiatric admission: 29%
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• 33% lifetime history of suicide attempts
• 13% currently suicidal/depressed
The report did not mention Attention Deficit/
Hyperactivity Disorders (ADHD) or Alcohol Related 
Neurodevelopental Disorders (ARND), two conditions 
that are more prevalent in inmate populations than in 
the general population. It is obvious from these statistics 
that OST inmates are high risk and need to be cared for 
by a team. CSC does provide the team. The OST team 
consists of the nurse, the parole officer, the program offi-
cer and the physician. CSC provides access to psycholo-
gists, psychiatrists, various specialists and even residen-
tial care in a Regional Psychiatric Centre if indicated.
AVAILABLE RESULTS
OST in CSC has met with a considerable measure of 
success. Institutional adjustment is much better in OST 
patients. They have fewer positive urine toxicology tests, 
participate better in program, complete more programs, 
and receive significantly fewer disciplinary charges than 
they did prior to starting OST.4 Both men and women 
participating in OST are more likely to be paroled than 
offenders with identified opioid use offenders not on 
OST. After release OST participants who continue treat-
ment under supervision in the community were less like-
ly to be returned to custody or to reoffend than offenders 
who terminated the OST involvement upon release or 
who were untreated.5
CONCLUSION
The introduction of OST in the correctional system has 
provided the best set of treatment data available from 
the system. It is hoped that the management of other 
substances will receive similar attention.
REFERENCES
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“Swimming against the Tide” Restricting Prescribing 
Practices in a Prison: A Personal Journey
David Francis Craig MD MSc
ABSTRACT
Objectives: I sought to reduce the unnecessary prescrib-
ing of psychotropic medications with abuse potential, 
chiefly benzodiazepines (Valium-like drugs), HS seda-
tives (“sleeping pills”) and psychostimulants (e.g. meth-
ylphenidate [Ritalin]) in prison settings.
Method: After each patient/inmate was assessed, benzo-
diazepines and HS sedatives were tapered and stopped. 
Patients/inmates were restricted to no more than one 
antidepressant and no more than one antipsychotic agent; 
prescriptions for psychostimulants were also restricted.
Results: Other health care staff consistently reported 
that the overall mental health of inmates improved 
soon after these changes were implemented. Prison staff 
reported that incidents of “strong-arming” of inmates for 
medications decreased as did levels of prison violence. 
Prescription drug costs dropped substantially and 
psychiatrist visits dropped by approximately 75%.
Drug-seeking behaviors included complaints to the 
media, which was sympathetic, and to the College of 
Physicians and Surgeons of Newfoundland and Labrador, 
and eventually to a widely publicized peer review which, 
fortunately, endorsed my practices.
Conclusions: Reducing unnecessary prescribing rates 
of psychotropic drugs with abuse potential to prison 
inmates has beneficial effects on both health care costs 
and inmate well-being. However, dealing with public 
criticism for doing so is difficult.
Key words: drug-seeking; penitentiary; inmates
Objectifs : J’ai cherché à réduire la prescription inutile 
de médicaments psychotropes avec un potentiel d’abus, 
principalement les benzodiazépines (médicaments 
comme le Valium), les sédatifs HS (“sleeping pills”), et 
les psychostimulants (ex. : méthylphénidate [Ritalin]) en 
milieu carcéral.
Méthodologie : Suivant l’évaluation de chaque patient/
détenu, les doses de benzodiazépines et sédatifs HS 
étaient progressivement diminuées jusqu’à l’arrêt. Les 
patients/détenus étaient limités à un antidépresseur 
et une substance antipsychotique; les prescriptions de 
psychostimulants étaient aussi limitées.
Résultats : Le personnel médical signalait régulièrement 
que la santé mentale globale des détenus s’améliorait peu 
après que les changements soient mis en place. Le personnel 
carcéral a signalé une diminution des incidents impliquant 
la force avec d’autres détenus pour obtenir des médicaments 
et de la violence en prison. Les coûts liés à la prescription de 
médicaments ont diminué substantiellement et les visites 
en psychiatrie ont diminué d’environ 75%.
Les comportements toxicomaniaques incluaient des 
plaintes aux médias, qui étaient favorables, et au Collège 
des médecins et chirurgiens de Terre-Neuve et Labrador, 
puis à un examen par les pairs largement publicisé, qui 
ont approuvé ma pratique.
Conclusions : La diminution de prescription inutile de 
médicaments psychotropes avec un potentiel d’abus parmi 
les détenus a des effets positifs à la fois sur les coûts de 
soins de santé et le bien-être des détenus. Toutefois, faire 
face à la critique du public pour avoir agi ainsi est difficile.
Mots- clés : toxicomanie, pénitencier, détenus
INTRODUCTION
I am a psychiatrist and my residency program included 
a three-month rotation in forensic psychiatry, during 
which I attended four half-day clinics per week at Her 
Majesty’s Penitentiary in St. John’s, Newfoundland 
during the summer of 1986. Most patients/inmates there 
were seen weekly and were prescribed benzodiazepines 
and HS sedatives (i.e. “sleeping pills”) for extended peri-
ods despite their recognized abuse potential¹ and their 
indication for short-term use². This practice concerned 
me because it seemed to reinforce the very substance-use 
disorders which had led to the crimes for which many of 
these inmates had been incarcerated. 
About three years later, in April 1989, the local Canadian 
Broadcasting Corporation televised a documentary which 
was critical of prescribing practices at the penitentiary³.
“The prison is visited by both a doctor and a 
psychiatrist…. Many inmates say the medical 
services are used a lot. Some… Say they regard 
Author Institution:Memorial University
Author Contact: David F Craig, Department of Psychiatry 
 Health Sciences Center, St. John’s, NL A1B 3V6, Tel: (709) 777-6661, 
 Fax: (709) 777-4120, email: dcraig@mun.ca
Funding Statement: None 
Conflict of Interest: None
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the doctors as pill pushers….’The amount of 
prescription drugs in this prison is unreal’… ‘The 
doctors here give it away’.”
Several years later, in 1999 I was asked to take over the 
psychiatric practice at Her Majesty’s Penitentiary. Before 
agreeing to do so, I reminded the Director of Adult 
Corrections that my approach to prescribing psychotropic 
medications was conservative, that the Director should 
expect to receive complaints and that his options would 
be either to put up with me or to fire me. I later assumed 
responsibility for psychiatric services at three of the four 
other adult prisons across Newfoundland and Labrador. I 
assess approximately 50% of all inmates in these institu-
tions, usually shortly after they are incarcerated.
According to Bland et al.4, who published their findings in 
1990, the prevalence of any DSM IIIR mental disorder in 
adult male prisoners in provincial prisons in Edmonton, 
Alberta was 91.7%. The prevalence of substance use 
disorders was 87.2%, that of alcohol abuse or dependence 
78.9%, and that of drug abuse or dependence 50.6%. 
Bland et al.4 found prevalences of 56.7% for antisocial 
personality disorder, 22.8% for mood disorders, 16.7% 
for major depression, 4.4% for bipolar disorder, 15.6% 
for anxiety disorders, 2.2% for schizophrenia and 1.1% for 
cognitive impairment.
Bland’s figures for the prevalence of substance-use disor-
ders appear similar to those for the prison populations in 
Newfoundland and Labrador. The overwhelming major-
ity of inmates suffer from substance-use disorders, of 
whom approximately two thirds report alcohol misuse, 
approximately half report drug misuse, and approximately 
one quarter report misuse of both alcohol and of at least 
one other substance of abuse, excluding tobacco. The 
substances reportedly misused and the reported routes 
of misuse appear to have changed in parallel with similar 
changes across the Province over the past 16 years. Until the 
early 2000’s patients reported misuse of cocaine, of opiates 
other than codeine and of any substance misuse via the 
intravenous route only a few times per year; they now do 
so several times per clinic day. These changes seem to have 
followed substantial improvements in the economic lot of 
Newfoundland and Labrador. Abuse of certain prescrip-
tion drugs including oxycodone, hydromorphone and 
morphine, most benzodiazepines and HS sedatives, and 
methylphenidate has become particularly problematic in 
the prison settings where I work. Misuse of bupropion and 
of quetiapine has also been observed frequently. Similar 
misuse of these substances, particularly in prison facilities, 
has been reported in the literature5,6.
The prevalence of mood and anxiety disorders in prison is 
not straight-forward. About 50% of the inmates assessed, 
or about 25% of the total prison population, have pre-
existing prescriptions for antidepressants, usually in 
combination of benzodiazepines and/or HS sedatives, at 
the time of incarceration. They were presumably given 
diagnoses of depression sometime prior to their incar-
ceration. However their reported histories reveal that 
their complaints of depression are readily attributable 
to external stressors such as legal difficulties, disrupted 
relationships or lost jobs, usually in the context of ongo-
ing misuse of alcohol and/or drugs. They usually report 
transient, not persistent, depressed mood, nor do they 
exhibit “markedly diminished interest or pleasure in all 
or almost all activities most of the day, nearly every day”7. 
They lack the inappropriate feelings of guilt, worthless-
ness or hopelessness which are characteristic of a depres-
sive disorder. Their mental examinations are usually 
unremarkable. These patients/inmates appear to suffer 
from grief and/or adjustment disorders (i.e. overreac-
tions to normal stressors), not true depressive illnesses. 
Similarly, about 30% of the inmates assessed, or about 
15% of the total prison population, have pre-existing 
prescriptions for benzodiazepines and/or HS sedatives 
but not for antidepressants at the time of incarceration. 
They have presumably been diagnosed with an anxiety 
disorder at some point. However, the substantial major-
ity of these patients/inmates attribute their anxiety to 
external stressors similar to those reported by patients/
inmates complaining of depressed mood. Those patients/
inmates who report diagnoses of either social anxiety 
disorder or panic disorder almost invariably present 
with symptom(s) which are “attributable to the physi-
ological effects of a substance/medication”, namely their 
substances of abuse8.
While somewhere between 5% and 10% of patients/
inmates assessed report diagnoses of bipolar disorder, 
the substantial majority of these patients/inmates deny 
histories suggestive of either hypomania or mania, which 
are prerequisites for the diagnosis9. Many of these incor-
rect diagnoses may represent attempts to attribute anti-
social acts to episodes of mania or hypomania, and/or 
attempts to obtain prescriptions for quetiapine which has 
abuse potential, particularly in prison settings6.
This is not to say that prison inmates do not suffer from 
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mood or anxiety disorders or bipolar disorder. The preva-
lence of true depressive and/or anxiety disorders within 
the prison population appears to approximate that in the 
community at large, namely approximately 5% for each 
disorder among male inmates and 10% for each disorder 
among female inmates, and that the prevalence of bipo-
lar disorder also approximates that in the community at 
large, namely somewhere between 1% and 2% among 
inmates of either gender.
The prevalence of diagnoses of attention deficit disorder 
and of prescriptions for methylphenidate among inmates 
prior to incarceration appear to have risen several-fold 
over the past few years.  This apparent rise seems to be 
in parallel with the rise in the frequency of reports of 
cocaine misuse within the local community. Most of these 
patients/inmates report histories of misuse of either 
cocaine or methylphenidate. Most of them do not show 
objective evidence of inattentiveness, distractibility or 
hyperactivity following withdrawal of methylphenidate. 
The majority of patients/inmates with prescriptions for 
methylphenidate are soon caught either hoarding meth-
ylphenidate or diverting it to other inmates. Reports of 
both methylphenidate-seeking behaviors and general 
aggressiveness among prison inmates have consistently 
risen or fallen in parallel with the numbers of prescrip-
tions for methylphenidate within the prisons.
The prison inmates assessed tend not to be psychologi-
cally minded and to seek pharmacological solutions to 
non-pharmacological problems. They are also reluctant 
to talk to any non-inmate for any longer than absolutely 
necessary for fear of being labeled as informants or “rats” 
and subjected to brutality at the hands of their fellow 
inmates.
THE PROCESS OF CHANGE
Her Majesty’s Penitentiary, housing approximately 160 
adult males, the substantial majority of whom were 
between ages 18 and 40, was generating approximately 
80 psychiatric visits per week. Most of these patients/
inmates were being seen weekly and were prescribed a 
benzodiazepine two or three times per day, an HS seda-
tive, usually ethchlorvinyl (Placidyl) 100 mg and, in some 
cases an antidepressant, an antipsychotic agent, a mood 
stabilizer or some combination thereof. 
Prescribing practices for psychotropic agents were 
changed by applying the following guidelines. 
1.  Restriction of new prescriptions for HS sedatives to 
the occasional brief (3-5 day) prescription for acute 
situational insomnia; Existing prescriptions for HS 
sedatives are normally tapered and stopped, usually 
at a rate of approximately 0.5-1 standard dose (e.g. 
temazepam [Restoril] 15 mg or zopiclone [Imovane] 
3.75 mg) per day approximately once per week.
2.  Restriction of new prescriptions for benzodiazepine 
anxiolytics to the occasional brief (3-5 day) prescrip-
tion for acute situational anxiety or to acute withdraw-
al from alcohol, other sedatives or possibly stimulants 
and/or opiates, in which case the maximum duration 
of these prescriptions did not usually exceed three 
weeks. Existing prescriptions for benzodiazepines, 
other than for the purpose of treating epilepsy, are 
normally tapered and stopped in a fashion similar to 
that for existing prescriptions for HS sedatives. 
3.  Restriction of the simultaneous prescription of more 
than one antidepressant or of more than one antipsy-
chotic agent to “overlap” periods, during which one 
antidepressant or antipsychotic agent is introduced 
while the other is withdrawn, or to when a tricyclic 
antidepressant was prescribed as an analgesic, in 
which case attempts are normally made to treat both 
disorders with the tricyclic antidepressant. Existing 
prescriptions for more than one antidepressant or 
more than one antipsychotic agent are normally 
tapered at a rate of approximately 0.5 standard anti-
depressant or antipsychotic agent dose (e.g. parox-
etine [Paxil] 10 mg, risperidone (Risperdal) 1-2 mg) 
per day approximately once per week.
4.  Caution in prescribing quetiapine for indications 
other than the treatment of psychosis or bipolar 
disorder6. Existing prescriptions of quetiapine for 
either anxiety or insomnia are normally tapered at 
a rate of approximately 50 mg daily once per week, 
exercise similar caution in prescribing bupropion 
because of its abuse potential7. New prescriptions 
for bupropion are normally restricted to patients/
inmates suffering from depressive and/or anxiety 
disorders who either fail to respond to or are intol-
erant of SSRI and SNRI antidepressants (e.g. parox-
etine [Paxil] or venlafaxine [Effexor] respectively). 
Patients/inmates who are caught hoarding or divert-
ing either quetiapine or bupropion normally have 
these medications tapered and stopped and are then 
observed off all psychotropic medications for several 
weeks in order to assess their need for any psychotro-
pic medication. 
5. The principles governing prescriptions for psycho-
stimulants evolved over time. Existing prescriptions 
for psychostimulants for the treatment of reported 
attention deficit disorder in patients/inmates without 
histories of stimulant abuse/dependence were initially 
continued. However, it was soon observed that levels 
of “strong-arming” of inmates for methylphenidate 
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and of prisoner aggressiveness/violence consistently 
rose and the overall mental health of prison inmates 
consistently fell whenever rates of prescribing methyl-
phenidate rose and vice versa whenever these rates fell. 
I then learned of and began following the approach 
advocated by Applebaum9, namely that: a) to qualify 
for treatment, the inmate must have clinically signifi-
cant impairment in areas such as ability to function in 
the general prison population…; data on functioning… 
must be corroborated by collateral sources…”;b) “initial 
pharmacologic treatment is with non-stimulant medi-
cations… unless the inmate has clear contraindications 
or well-documented lack of response to adequate pass 
trials of non- stimulants”; c) “treatment with stimulants 
can occur only after failure of a complete trial of one 
or more non-stimulant agents, or when such trials are 
contraindicated…”; and d) “ongoing treatment requires 
documentation of objective improvement in function-
ing….Stimulant use must also be discontinued if the 
inmate diverts or otherwise misuses the medication.”
6. Methadone Maintenance Treatment patients/
inmates are normally continued on their pre-existing 
doses of methadone throughout their term of incar-
ceration in keeping with the guidelines of the College 
of Physicians and Surgeons of Newfoundland and 
Labrador. Regular communication regularly with 
the community methadone-prescribing physician is 
maintained throughout the terms of incarceration, 
particularly at the time of release. 
7. All patients/inmates whose medication(s) are tapered 
and stopped are followed for as long as is needed to 
ensure that they remain well off these medications. 
All patients/ inmates who are prescribed psychotro-
pic medications are followed throughout the course 
of their incarcerations, usually by monthly assess-
ment or more often if indicated.
RESULTS
The benefits of these changes became readily apparent 
almost immediately. Feedback from staff was highly posi-
tive namely to the effect that inmates were now alert and 
able to attend to their programs; that rates of drug diversion, 
possession of contraband, “strong-arming” of inmates for 
their medications and of violence in general were decreas-
ing substantially and that the overall mental well-being of 
inmates were improving. Unfortunately, data to confirm 
and measure the extent of these reported improvements 
were not gathered. The overall cost of psychotropic medica-
tions dropped considerably and the number of psychiatric 
visits dropped by approximately 75%.
The patients/inmates whose psychotropic medications 
were tapered and stopped were dismayed but reluctantly 
accepted the changes as inevitable. Some later informed 
the penitentiary nurse that “that b****** was right”, and 
that they felt more “clear-headed” after their psychotro-
pic medications were discontinued.
Patients/inmates soon complained to the media, which 
published stories which were inevitably sympathetic 
to the patient/inmate. The demands of confidentiality 
effectively preclude the media from obtaining corrobo-
rative or contradictory information, resulting in a publi-
cation of very one-sided stories, leaving me without 
recourse. Other protests took the form of approximately 
35 complaints to the College of Physicians and Surgeons 
of Newfoundland and Labrador which conducted formal 
investigations of each complaint.
The Citizens’ Representative, an appointee of the 
Provincial legislature, took it upon himself to conduct an 
investigation10. His report concluded that:
“Inmates should have the reasonable expectation that 
they will receive the same type and level of medical care 
which is available to all citizens…. It is important that the 
psychiatric services provided at our correctional institu-
tions be… at least similar and equivalent to that avail-
able to all citizens…. We conclude that the reasonable 
expectations of inmates with respect to the prescription 
of psychiatric drugs are not being met by the Department 
for the following reasons: the Department is fully aware 
of conservative prescription practices of the psychiatrist…. 
Patients in the community who are unhappy with his 
conservative prescription practices are free to seek autho-
rized prescription drugs elsewhere…. Thus the control 
made possible by incarceration is a distinguishing feature 
in how inmates versus patients (in the community) are 
treated…. We conclude that to continue to retain him (the 
author) to provide psychiatric services for the Provincial 
correctional facilities is unreasonable, unjust and oppres-
sive to inmates….” The government rejected the Citizens’ 
Representative’s report on the basis that it was not a peer 
review. The Minister of Justice then ordered a peer review, 
to which I consented in advance. This peer review took 
approximately 18 months to complete. Meanwhile public 
criticisms continued12, 13, 14. 
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The peer review concluded that “Dr. Craig is clearly prac-
ticing to an acceptable standard.… His understanding of 
diagnosis, and medication management, is good, and he 
is familiar with unique aspects of prescribing in correc-
tional settings…. A number of commonly used psychotro-
pic medications have potential for abuse, in correctional 
settings, with possible health and security consequences 
for inmates, and the institution…. The controlled setting 
of corrections can provide an opportunity for reevaluation 
of the need for certain medications, and the opportunity 
to discontinue unnecessary treatment…” The subsequent 
silence from all critics was immediate and persistent.
DISCUSSION
While mental illnesses are highly prevalent in correctional 
facilities, the predominant mental illnesses by far are 
substance-use disorders. While diagnoses of other mental 
disorders, particularly of mood and anxiety disorders, bipo-
lar disorder and attention deficit disorder are very common, 
the majority of these diagnoses appear to me to be incor-
rect, the appropriate diagnoses appearing to be adjustment 
disorders, substance use disorders or some combination 
thereof. The true prevalence of mood and anxiety disorders 
and bipolar disorder in prisons probably approximates that 
in the community at large. The recent apparent dramatic 
rise in the local prevalence of diagnoses of adult atten-
tion deficit hyperactivity disorder among prison inmates 
appears largely attributable to an equally dramatic rise in 
reports of cocaine misuse in local communities.
Common drug-seeking behaviors among prison inmates 
include choosing family physicians and/or psychiatrists 
who appear predisposed to prescribing psychotropic 
medications with abuse potential and complaining to the 
media and to authority figures when these medications 
are discontinued. The constraints imposed by the duty 
of confidentiality preclude healthcare professionals and 
organizations from saying anything in response to these 
complaints, as a result of which the public is exposed to a 
very one-sided version of events. The ensuing public and 
harsh criticism is difficult to deal with and is likely to deter 
other prescribers from similar attempts to cut down on the 
prescription of psychotropic drugs with abuse potential.
CONCLUSION
In hindsight, it is regrettable that before and after 
measures of patient/inmate well-being, Disciplinary 
Court convictions for drug-diversion, possession of 
(drug) contraband, “strong-arming” and other forms 
of inmate-on-inmate and inmate-on-staff violence and 
recidivism rates were not taken and compared to contem-
poraneous rates in similar prisons where prescribing 
habits were not changed. Another prison contemplat-
ing the adoption of a structured medication use policy 
such as that described above would be wise to take these 
before-and-after measures, both to (hopefully) confirm 
and measure the favorable impact of these changes.
If society is to curtail prescription drug abuse, we must 
both discourage physicians from inappropriately prescrib-
ing drugs with abuse potential and encourage physicians 
to taper and stop prescriptions for these medications when 
they are no longer required. Where appropriate, educa-
tion of health care providers about addiction issues and/or 
enforcement measures should then be taken. This should 
be a responsibility of the Provincial Colleges of Physicians 
and Surgeons which should also streamline the process of 
investigating minor complaints in order to reduce the extent 
to which threats of such complaints deter physicians from 
refusing inappropriate requests for prescriptions for drugs 
with abuse potential. Finally, education about addiction-
related issues should become part of the curriculum of all 
medical and other health care-related schools.
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ABSTRACT
Information collected, collated, and disseminated by the 
Canadian Community Epidemiology Network on Drug 
Use (CCENDU) on the emergence of fentanyl or fentanyl 
analogues for sale in the illicit marketplace is presented 
as an example of how CCENDU has functioned as a 
Canadian early warning system to detect and disseminate 
reliable, timely information on alcohol and other drug 
related harms. In July 2013, the network issued its first 
alert on the sale of fentanyl or fentanyl analogues in the 
illicit drug marketplace. In February 2014, the network 
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issued a second alert on the appearance of fentanyl 
powder that had been pressed into tablets in order to 
resemble oxycodone tablets. A year later (February 2015), 
the network issued a third alert indicating that partners 
were reporting increased incidences of fatal and non-
fatal overdoses suspected or confirmed to involve illicit 
fentanyl. In August 2015, more than two years follow-
ing the first alert, the network issued a bulletin on the 
marked increase in the number of deaths involving 
fentanyl in Canada between 2009 and 2014. This paper 
discusses the value and importance of a Canadian early 
warning monitoring and surveillance system to detect 
and disseminate reliable timely information on alcohol 
and other drug related harms.
L’information recueillie, synthétisée et diffusée par 
le Réseau communautaire canadien d’épidémiologie 
des toxicomanies (RCCET) concernant l’apparition du 
fentanyl ou d’analogues du fentanyl sur le marché illic-
ite est présenté comme un exemple du fonctionnement 
du RCCET en tant que système d’alerte rapide canadien 
permettant de relever et de diffuser en temps opportun de 
l’information fiable sur les méfaits de l’alcool et d’autres 
drogues. En juillet 2013, le réseau a émis sa première 
alerte concernant la vente de fentanyl ou d’analogues 
du fentanyl sur le marché des drogues illicites. En 
février 2014, le réseau a émis une deuxième alerte, sur 
l’apparition de fentanyl en poudre transformé en compri-
més de façon à ressembler à des comprimés d’oxycodone. 
Un an plus tard, en février 2015, le réseau a émis une 
troisième alerte s’appuyant sur la hausse du nombre de 
cas soupçonnés ou confirmés de surdoses mortelles ou 
non mortelles impliquant du fentanyl illicite signalées 
par des partenaires. La présente étude porte sur la valeur 
et l’importance d’un système canadien de surveillance 
et d’alerte rapide permettant de relever et de diffuser en 
temps opportun de l’information fiable sur les méfaits 
liés à l’alcool et aux autres drogues.
THE RISE OF OVERDOSE DEATHS 
INVOLVING FENTANYL AND THE 
VALUE OF EARLY WARNING
Harms arising from alcohol and other drug use are an 
issue of public health concern in Canada. Between 2009 
and 2014 there were over 1,000 deaths involving fentanyl 
in Canada1. Further the number of deaths per year in 
Canada’s largest provinces increased markedly during this 
time – in some provinces increasing more than 20 times. 
Some of the fentanyl that has appeared on the market 
since 2013 has been in pill or powder form, and often 
mistaken for other drugs such as oxycodone or heroin. 
Many anecdotal reports suggest that fentanyl overdoses 
occurred among individuals who thought they were 
using heroin, oxycodone, cocaine or another substance, 
but mistakenly took fentanyl; thus increasing the risk 
of overdose. It is possible that many of these overdoses 
could have been prevented if the emergence of fentanyl 
into the illicit drug marketplace had been detected and 
acted upon early, by warning drug using populations 
and or increasing availability and access to drugs such as 
naloxone. In order to effectively develop and implement 
interventions to prevent and reduce harms, systematic 
collection, analysis, interpretation, and dissemination of 
timely and accurate information on the availability, use, 
and harms associated with new drugs and new drug use 
trends is essential.
THE CANADIAN COMMUNITY 
EPIDEMIOLOGY NETWORK ON DRUG 
USE 
CCENDU (www.CCENDU.ca) is a national, sentinel 
surveillance network coordinated by the Canadian Centre 
on Substance Abuse (CCSA) that is made up of represen-
tatives from Newfoundland and Labrador, Nova Scotia, 
Québec, Montréal, Toronto, Winnipeg, Saskatchewan, 
Alberta, and British Columbia. Each representative 
collects quantitative information on drug harms from 
local data sources (e.g., poison control centres, coroners) 
and anecdotal reports from those directly working with 
drug-using populations (e.g., law enforcement, harm 
reduction programs), and people who use drugs. This 
information is then collated and the risk assessed at the 
national level. If warranted, CCENDU issues alerts to 
advise first responders, healthcare practitioners, treat-
ment providers, people who use drugs, law enforcement, 
and others about drug-related health threats and what 
can be done to prevent and reduce harms. 
EARLY DETECTION OF THE EMERGENCE 
OF ILLICIT FENTANYL 
Fentanyl is an opioid analgesic that is prescribed medici-
nally to treat pain. Until 2013, fentanyl in the illicit drug 
marketplace was primarily diverted prescription-grade 
fentanyl in the form of transdermal patches. However, 
in May 2013, members of CCENDU and related partner 
organizations began sharing anecdotal reports regard-
ing the availability of fentanyl in powder and tablet form 
(i.e., illicit fentanyl). 
Although misuse of pharmaceutical grade fentanyl can 
result in overdose or other health complications, illicit 
fentanyl poses an even greater health threat for a number 
of reasons. First, illicit fentanyl is not regulated and there 
is no quality control. This means that the amount and 
type of fentanyl analogue in an illicitly produced pill or 
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powder is unknown and can be highly variable. Second, 
the range between the effective and lethal dose can be 
much narrower in fentanyl analogues such as α- methyl 
fentanyl than prescription-grade fentanyl2. Third and 
most importantly, individuals may mistakenly take 
fentanyl products thinking they are heroin, oxycodone, 
or another non-opioid substance placing them at greater 
risk of an accidental overdose or other adverse health 
effects. 
EARLY INFORMATION SHARING ON 
ILLICIT FENTANYL BY CCENDU
In late May 2013, the British Columbia Office of the 
Provincial Health Officer issued an information bulletin 
indicating there had been 23 suspected fentanyl-related 
deaths during the first four months of 20133. In June 2013, 
CCENDU released a national alert on the issue4. By early 
2014, CCENDU members reported that counterfeit oxyco-
done pills containing fentanyl were becoming increas-
ingly available. Pills were frequently green, stamped 
with “CDN” on one side and “80” on the other and were 
colloquially referred to as “green jellies” or “street oxy” in 
western Canada and “green monsters” or “green beans” 
in eastern Canada. In addition there were also reports 
of white pills that were stamped with the number 10 in 
place of the 80 - emerging on the street. These prod-
ucts were reported by partners (from November 2013 to 
February 2014) first in British Columbia, then in Alberta, 
followed by Newfoundland and Labrador. Laboratory 
analyses conducted in February 2014 of seized green and 
white tablets by Health Canada’s Drug Analysis Service 
(DAS) indicated that the pills contained fentanyl 89% of 
the time. In response to these findings, CCENDU issued 
a second alert to advise Canadians of this public health 
threat5. 
By the end of 2014, reports began to emerge of increas-
ing fatal and non-fatal overdoses that may be related to 
inadvertent use of illicit fentanyl among those thinking 
they were taking other drugs. Increases in deaths involv-
ing fentanyl were reported in both British Columbia6 and 
Alberta. In response, CCENDU issued a third alert warn-
ing that illicit fentanyl appeared to be responsible for an 
increase in both fatal and non-fatal overdoses7. In March 
2015, alerts were issued in Alberta by the RCMP8, in the 
United States by the Drug Enforcement Administration 
(DEA) 9, and a large social media campaign was launched 
in British Columbia to warn people about the risks associ-
ated with illicit fentanyl (see www.knowyoursource.ca). 
In August 2015 the CCENDU network released a bulletin 
on deaths involving fentanyl10 indicating that between 
2009 and 2014 there were more than 650 deaths in 
Canada where fentanyl was either a cause or contribut-
ing cause. The release of the bulletin in conjunction with 
media outreach by partners in British Columbia, Québec, 
and elsewhere brought a great deal of attention to the 
issue. Between August 11 and August 18 there were almost 
700 media stories released that referred to the bulletin 
including several high-profile editorials and commen-
taries from the Globe and Mail11,12 , statements from the 
Canadian Pharmacists Association13, and news confer-
ences held by Toronto Police Services as well as Winnipeg 
Police Services. The attention also included a joint state-
ment from Health Canada and the Public Health Agency 
of Canada warning the public about the dangers of 
illicit fentanyl indicating that they were reviewing the 
prescription-only status of the opioid overdose treatment 
Naloxone on an urgent basis14.
THE VALUE OF EARLY WARNING 
In order to effectively develop and implement interven-
tions to prevent and reduce harms associated with new 
drugs and new drug use trends, systematic collection, 
analysis, interpretation, and dissemination of timely and 
accurate information is essential. Unfortunately, most 
surveillance information describing the harms associated 
with drug misuse15,16 relies on lagging indicators of drug 
use available from population surveys (e.g., Canadian 
Community Health Survey, student drug use surveys) 
or administrative databases (e.g., coroners data, hospi-
tal discharge data). The time lag between when these 
sources of data are available, analysed, and published 
can be a year or more. By this time any new drug or new 
drug use trend could have either established itself and 
caused significant harm or caused significant harms and 
disappeared. 
While other jurisdictions have early warning systems 
designed to detect and disseminate information on drug-
related harms, there is currently no such formal, estab-
lished Canadian early warning system. In the United 
States the National Institute on Drug Abuse (NIDA) 
funds the National Drug Early Warning System (NDEWS; 
http://www.ndews.org/) and in Europe the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) operates the European Union Early Warning 
System (http://www.emcdda.europa.eu/themes/new-
drugs/early-warning). In Canada, CCENDU has served 
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as an informal community monitoring and surveillance 
network since 1995. However, it has only been since 2012 
that a new revitalized CCENDU began to focus on the 
dissemination of reliable, timely information on alcohol 
and other drug related harms and possible responses to 
those harms. Since this change in focus it has become 
more known to law enforcement, first responders, 
healthcare practitioners, treatment providers, people 
who use drugs, and others with an interest in timely 
information on drug use trends or other related topics of 
immediate concern.
In addition to detecting and disseminating information 
on illicit fentanyl as early as May 2013, CCENDU notifica-
tions have also been issued on a number of other impor-
tant drug-related issues such as “bath-salts”17, the misuse 
of opioids in Canadian communities18; unconfirmed 
reports of desomorphine (“Krokodil”)19; synthetic canna-
binoids20, and drug-related harms at Canadian music 
festivals21. Between September, 2014 and September, 
2015 the number of professionals who have voluntarily 
subscribed to receive these notifications increased over 
400% to over 700 indicating a strong interest in accessing 
this type of information. During this same time period 
there have been over 800 media stories referring to 
CCENDU Alerts, mainly those regarding illicit fentanyl. 
Further the three alerts on fentanyl issued by the network 
have been accessed from the CCSA website over 30,000 
times. There have also been anecdotal reports that, owing 
to the alerts, first responders arriving at the scene of an 
overdose and seeing green pills knew exactly what they 
were dealing with and were able to respond accordingly. 
However, CCENDU operates largely as a volunteer 
organization nationally coordinated and supported by 
the CCSA and the capacity of the various CCENDU site 
coordinators varies considerably. Increasing the capacity 
of CCENDU to operate as a formal early warning system 
would improve Canada’s ability to detect and rapidly 
disseminate emerging drug use trends and further 
protect the health of at-risk Canadians.
The need for an effective early warning system is unlikely 
to diminish. Relatively recent large-scale changes in 
the recreational illicit drug market owing to the rise in 
the abuse and misuse of prescription drugs22 as well as 
the introduction of a large number of new synthetic 
drugs (some controlled and some not), has blurred the 
line between what is illicit and non-illicit drug use and 
increased the importance of early warning surveillance 
intelligence. There are several data sources in Canada that 
could be more widely and more regularly used to moni-
tor new and emerging drug use trends. Such data sources 
include data from poison control centres23, hospital 
emergency departments24, first responders (ambulance 
data), or media25 etc.
CONCLUSION
Harms arising from alcohol and other drug use are an 
issue of public health concern in Canada. The fentanyl 
crisis has raised many questions regarding health poli-
cies concerning access to substance abuse treatment, 
availability of community naloxone programs, and the 
unintended consequences of diversion controls on 
psychoactive prescription pharmaceuticals. It has also 
highlighted the value and importance of early detection 
and dissemination of information on new drugs and new 
drug use trends. Increasing the capacity of CCENDU to 
become a more fully developed Canadian early warning 
system that detects and rapidly disseminates information 
on drug-related health threats to people who use drugs, 
first responders, healthcare practitioners, treatment 
providers, and law enforcement is essential in order to 
protect the health of Canadians. Health professionals in 
the field of addiction medicine are a key group since they 
can both report observed front line drug use and also 
(report) harms from drugs as reported by users. They can 
also benefit from the information provided in CCENDU 
publications. Engagement or collaboration with these 
health providers would ideally occur with the local 
CCENDU site coordinator, strengthening local surveil-
lance, health protection and promotion. This would in 
turn would contribute to the national system. If you are 
interested in becoming involved or learning more about 
CCENDU please visit www.ccendu.ca or send an email to 
ccendu@ccsa.ca.
REFERENCES 
1. CCENDU Bulletin: Deaths Involving Fentanyl in Canada 
(2009-2014). Ottawa (ON): Canadian Centre on Substance 
Abuse, 2015. (Accessed September 30, 2015, at http://www.
ccsa.ca/Resource%20Library/CCSA-CCENDU-Fentanyl-
Deaths-Canada-Bulletin-2015-en.pdf).
2. Higashikawa Y, Suzuki S. Studies on 1-(2-phenethyl)-4-(N-
propionylanilino)piperidine (fentanyl) and its related 
compounds. VI. Structure-analgesic activity relationship for 
fentanyl, methyl-substituted fentanyls and other Analogues. 
Forensic Toxicology 2008;26:1-5.
3. Health workers urged to watch for suspicious overdoses. 
Victoria (BC): British Columbia Office of the Provincial 
Health Officer; 2013. (Accessed July 8, 2015, at http://www.
health.gov.bc.ca/pho/media/pdf/IB_fentanyl_May%2029.
pdf).
4. CCENDU Drug Alert: Illicit Fentanyl. Ottawa, (ON): 
Canadian Centre on Substance Abuse; 2013. (Accessed July 
8, 2015, at http://www.ccsa.ca/Resource%20Library/CCSA-
CCENDU-Drug-Alert-Bath-Salts-2012-en.pdf).
V
O
L
U
M
E
 6
 N
O
. 3
17
CJA JCA
5. CCENDU Drug Alert: Increasing Availability of Counterfeit 
Oxycodone Tablets Containing Fentanyl. Ottawa, ON: 
Canadian Centre on Substance Abuse; 2014. (Accessed July 
8, 2015, at http://www.ccsa.ca/Resource%20Library/CCSA-
CCENDU-Oxycontin-Fentanyl-Alert-2014-en.pdf).
6. Jafari S, Buxton JA, Joe R. Rising fentanyl-related overdose 
deaths in British Columbia. Canadian Journal of Addiction. 
2015;6(1):4-6.
7. CCENDU Drug Alert: Fentanyl-related Overdoses. Ottawa, 
(ON): Canadian Centre on Substance Abuse; 2015. (Accessed 
July 8, 2015, at http://www.ccsa.ca/Resource%20Library/
CCSA-CCENDU-Drug-Alert-Fentanyl-related-Overdoses-
2015-en.pdf).
8.  Growing use of illicit fentanyl cause for concern in Alberta. 
Edmonton, (AB): Royal Canadian Mounted Police; 2015. 
(Accessed July 8, 2015, at http://www.rcmp-grc.gc.ca/ab/
news-nouvelles/2015/150318-fentanyl-eng.htm). 
9.      DEA Issues Nationwide Alert on Fentanyl as Threat to Health 
and Public Safety. Washington (DC): United States Drug 
Enforcement Administration; 2015. (Accessed July 8, 2015, at 
http://www.dea.gov/divisions/hq/2015/hq031815.shtml).
10. CCENDU Bulletin: Deaths Involving Fentanyl in Canada 
(2009-2014). Ottawa, ON: Canadian Centre on Substance 
Abuse; 2015. (Accessed October 15, 2015, at http://www.ccsa.
ca/Resource%20Library/CCSA-CCENDU-Fentanyl-Deaths-
Canada-Bulletin-2015-en.pdf. 
11.  Fentanyl is killing people, so why doesn’t Ottawa say some-
thing? Toronto, ON: The Globe and Mail; August 11, 2015. 
(Accessed Ocyober 15, 2015, at http://www.theglobeandmail.
com/globe-debate/editorials/fentanyl-is-killing-people-so-
why-doesnt-ottawa-say-something/article25932570/ ).
12. Why is an opiate antidote harder to obtain than the drug? 
Toronto, ON.: The Globe and Mail, 2015. (Accessed September 
30, 2015, at http://www.theglobeandmail.com/globe-debate/
why-is-an-opiate-antidoteharder-to-obtain-than-the-drug/
article25959264/).
13. CPhA Statement on Fentanyl Misuse. Ottawa ON: Canadian 
Pharmacists Association, 2015. (Accessed September 30, 
2015, at http://www.pharmacists.ca/index.cfm/advocacy/
advocacy-activities/cpha-statement-on-fentanyl-misuse/).
14. Joint Statement on Fentanyl - Dr. Supriya Sharma, Health 
Canada Chief Medical Advisor and Dr. Gregory Taylor, Chief 
Public Health Officer of Canada. Ottawa ON. (Accessed 
September 30, 2015, at http://news.gc.ca/web/article- 
en.do?mthd=index&crtr.page=1&nid=1015309 ).
15. Young MM, Jesseman R. The impact of substance use 
disorders on hospital use. Ottawa, ON: Canadian Centre on 
Substance Abuse, 2014. (Accessed July 8, 2015, at http://www.
ccsa.ca/Resource%20Library/CCSA-Substance-Use-Hospital-
Impact-Report-2014-en.pdf).
16. Gomes T, Mamdani MM, Dhalla IA, Cornish S, Paterson JM, 
Juurlink DN. The burden of premature opioid-related mortal-
ity. Addiction. 2014.
17. CCENDU Drug Alert: “Bath Salts”. Ottawa (ON): Canadian 
Centre on Substance Abuse; 2012. (Accessed July 8, 2015, at 
http://www.ccsa.ca/Resource%20Library/CCSA-CCENDU-
Drug-Alert-Bath-Salts-2012-en.pdf).
18. CCENDU Bulletin: Misuse of opioids in Canadian commu-
nities. Ottawa (ON): Canadian Centre on Substance 
Abuse; 2013. (Accessed July 8, 2015, at http://www.ccsa.
ca/Resource%20Library/ccsa-CCENDU-Opioid-Bulletin-
2013-en.pdf).
19. CCENDU Bulletin: No confirmed reports of desomorphine 
(“Krocodil”/”Crocodile”) in Canada. Ottawa (ON): Canadian 
Centre on Substance Abuse; 2013. (Accessed July 8, 2015, at 
http://www.ccsa.ca/Resource%20Library/ccsa-CCENDU-
Desomorphine-Bulletin-2013-en.pdf).
20. CCENDU Bulletin: Synthetic Cannabinoids in Canada. 
Ottawa (ON): Canadian Centre on Substance Abuse; 2014. 
(Accessed July 8, 2015, at http://www.ccsa.ca/Resource%20
Library/CCSA-CCENDU-Synthetic-Cannabis-Bulletin-2014-
en.pdf).
21. Canadian Community Epidemiology Network on Dug Use. 
CCENDU Bulletin: Drug-related Harms at Canadian Music 
Festivals. Ottawa, ON: Canadian Centre on Substance 
Abuse, 2014. (Accessed July 8, 2015, at http://www.ccsa.ca/
Resource%20Library/CCSA-CCENDU-Synthetic-Cannabis-
Bulletin-2014-en.pdf ).
22. First do no harm: Responding to Canada’s prescription 
drug crisis. Ottawa(ON): National Advisory Committee on 
Prescription Drug Misuse, 2013. (Accessed July 8, 2015, at 
http://www.ccsa.ca/resource%20library/canada-strategy-
prescription-drug-misuse-report-en.pdf.
23. Number of calls to US poison control centers about exposure 
to synthetic marijuana and synthetic cathinones stable at 
lower levels than recent years. Baltimore (MD): Center for 
Substance Abuse Research, 2013. (Accessed July 8, 2015, at 
http://www.cesar.umd.edu/cesar/cesarfax/vol22/22-32.pdf.
24. The DAWN Report: Drug-Related Emergency Department 
Visits Involving Synthetic Cannabinoids. Rockville (MD): 
Center for Behavioral Health Statistics and Quality, 2012. 
(Accessed July 8, 2015, at http://archive.samhsa.gov/
data/2k12/DAWN105/SR105-synthetic-marijuana.pdf).
25. Young MM, Dubeau C, Corazza O. Detecting a signal in the 
noise: Monitoring the global spread of novel psychoactive 
substances using media and other open source information. 
Human Psychopharmacology: Clinical and Experimental, 
2015; 30: 319-326.
18
D
EC
E
M
B
E
R
 2015
Case-Control Study of Risks and Causes of Death  
Amongst Opioid Dependent Patients on Methadone 
Maintenance Treatment 
Dr Edyta Truszkowska MRCPsych, MB BS1, Dr Peter McCarron MRCPsych, PhD, MB, BCh, BAO2, Dr Pavel Konovalov MD, PhD, DCP2, Dr 
Tahir Galander MRCPsych, MB BS2, Dr Suzi Lyons3, Dr Eamon Keenan MRCPsych MB BCh1, Dr Bobby P Smyth MRCPsych MB BCh BAO4
ABSTRACT
Objectives: International studies indicate that metha-
done maintenance treatment (MMT) reduces mortal-
ity in patients with opioid use disorder, but mortality 
remains elevated compared to that of the general popula-
tion. This study investigated risk factors impacting upon 
mortality among patients on MMT. 
Methods: The study was conducted at an addiction treat-
ment clinic. We utilised a case-control design matching all 
deaths occurring between February 2005 and February 2012 
inclusive with another attendee in terms of age and gender.
Results: There were 80 deaths with median age 35 years 
(inter quartile range (IQR) 30-41 years). The causes of 
death were categorised as poisoning (48%), medical 
(36%) and trauma (16%). The median methadone dose 
of cases was 70mg (IQR 55-90) and was not significantly 
different from the control group (median 80mg, IQR60-
90, p=0.58). There was no significant difference between 
the fatalities and the controls in terms of recent misuse 
of cocaine. Cases were more likely to have a history of 
imprisonment (71% versus 35%, p<0.001), HIV infection 
(29% versus 12%, p=0.01) and non-HIV related medi-
cal problems (47% versus 16%, p<0.001). They were also 
more likely to have missed attendance at the clinic for at 
least one week (23% versus 1%, p<0.001). 
Conclusions: Methadone dose was not associated with 
increased mortality. A life history of imprisonment (not 
only recent release) was a marker for increased risk of 
death while on MMT. Treatment non-attendance was asso-
ciated with increased mortality and services should seek to 
actively follow-up on patients who drop out of treatment.
Key words: opioid use disorder, methadone mainte-
nance, mortality, poisoning
Objectifs: Des études internationales montrent que le 
traitement de maintien à la méthadone (TMM) réduit la 
mortalité chez les patients avec des troubles de consom-
mation d’opioïdes mais que la mortalité demeure élevée 
en comparaison avec la population générale. Cette étude 
a examiné les facteurs de risque ayant un impact sur la 
mortalité parmi des patients sous TMM.
Méthodologie: L’étude s’est déroulée dans une clinique de 
traitement des dépendances. Nous avons utilisé un devis 
d’étude cas-témoin et apparié avec un patient de la clinique, 
sur la base de l’âge et du genre, tous les décès survenus entre 
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les mois de février 2005 et février 2012 inclusivement.
Résultats: Il y a eu 80 décès dont l’âge médian était de 
35 ans (écart interquartile (EI) 30-41 ans). Les causes de 
décès ont été catégorisées comme suit : empoisonnement 
(48%), médical (36%) et trauma (16%). La dose médi-
ane de méthadone des cas était de 70 mg (EI 55-90) et 
n’était pas significativement différente du groupe témoin 
(médiane 80 mg, EI 60-90, p=0,58). Il n’y avait aucune 
différence significative entre les cas et les témoins quant à 
l’abus récent de cocaïne. Les cas étaient plus susceptibles 
d’avoir un historique d’emprisonnement (71% versus 
35%, p<0.001), d’être infectés par le VIH (29% versus 
12%, p=0.01) et d’avoir des problèmes médicaux non-
reliés au VIH (47% versus 16%, p<0.001). Ils étaient aussi 
plus susceptibles d’avoir manqué leurs rendez-vous à la 
clinique pendant une période d’au moins une semaine 
(23% versus 1%, p<0.001).  
Conclusions: La dose de méthadone n’était pas associée 
à une augmentation de la mortalité. Avoir été empris-
onné à vie (pas seulement une libération récente) était 
un indicateur d’un plus grand risque de décès pendant 
un TMM. Manquer des traitements était associé avec une 
augmentation de la mortalité et les services devraient 
envisager suivre activement les patients qui abandon-
nent leur traitement.
Mots clés : troubles de consommation d’opioïdes, main-
tien à la méthadone, mortalité, empoisonnement
OBJECTIVES
Evidence indicates that mortality is higher amongst individ-
uals with problem alcohol or drug use1. Mortality rates are 
particularly elevated amongst those with sever opioid use 
disorder, especially injecting drug users (IDU)2-4 and around 
50% of IDU die within 30 years follow-up5,6. Methadone 
maintenance treatment (MMT) produces a 29 to 85% 
reduction in mortality among IDU who adhere to MMT for 
at least one year7-9. Nevertheless, mortality remains elevated 
in MMT groups in comparison to the general population3,4. 
Common causes of death among drug users include acci-
dental overdose, blood-borne viral infections such as HIV, 
HCV, HBV10,11, other health complications, suicide and 
deaths due to trauma3,4 and sudden unexplained death4. 
Factors identified as increasing all-cause mortality among 
those on MMT include a methadone dose below 60 mgs12, 
medical co-morbidity13, HIV infection14, alcohol misuse15 
and a history of psychiatric admissions3,13,15. Previous 
psychiatric admissions together with co-prescription of 
benzodiazepines were associated with drug-dependent 
deaths in Scotland13. Characteristics such as younger age on 
commencing treatment, living with a partner/spouse, not 
abusing benzodiazepines on treatment commencement8 
and remaining in treatment8,15,16 are predictors of survival. 
Many of these deaths due to accidental overdose occur 
subsequent to a reduction in opioid tolerance following a 
period of abstinence, such as after detoxification17 or after 
release from prison18. People, who exit MMT, for what-
ever reason, experience a substantially increased short-
term risk of accidental overdose. In a UK multi-site study 
the risk of a fatal overdose was 2.3% in the first month out 
of treatment, falling to under 1% thereafter17. 
Poly-substance use, heavy drinking and use of benzo-
diazepines are contributors to drug toxicity and fatal 
overdose3. Among individuals on MMT who also have 
problem cocaine use, there is increased prevalence of risk 
behaviours including more frequent injecting, injecting 
unsafely, having more sex partners, using more heroin, 
greater criminal activity and more frequent incarcera-
tion19. In addition, illicit drug use, especially of opiates, 
benzodiazepines and cocaine, was noted to negatively 
impact adherence to MMT8. In Ireland, the Health 
Research Board reported an increased number of poison-
ing deaths between 2005 and 201120 and in 2011 59% of 
those deaths involved polysubstance poisoning. 
The existing evidence suggests that higher doses (above 
60 mg daily) of methadone reduce the risk of death when 
compared with lower doses12. An increase in average 
methadone dose above 75 mg/day was associated with 
a 24% reduction in mortality21. Conversely, dose-related 
QTc prolongation (especially in doses over 100mg/day) 
may be responsible for a number of sudden deaths22. 
Besides methadone dose, impaired liver function 
(common among drug users), presence of cytochrome 
P-450 3A4 inhibitors (antipsychotics, antidepressant 
and other), and additional depressive agents (benzodi-
azepines, alcohol) may contribute to poisoning deaths 
involving methadone23. 
A recent study confirmed the high mortality among 
IDUs in Ireland6. Over a 25-year follow-up of IDUs, 63% 
had died, with more than half of these deaths due to 
HIV-related diseases6. Other studies of MMT patients 
have confirmed elevated mortality in individuals with 
HIV infection14,16,21. The development of anti-retroviral 
therapy (ART) has reduced mortality among HIV-infected 
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IDU, but adherence to ART is frequently poor21.
This study sought to explore risk factors related to mortal-
ity amongst individuals on MMT. We hypothesised that 
lower methadone dose and problem use of cocaine and/
or benzodiazepines is associated with increased mortal-
ity. We specifically sought to examine factors associated 
with poisoning deaths.
METHOD
SETTINGS
There was an increase in the incidence of heroin use in 
Dublin, Ireland in the mid-1990s24. In response, treat-
ment services were expanded and MMT became the 
mainstay of treatment. The Central Treatment List (CTL) 
was established to record data on every individual in 
receipt of MMT and patients can only be treated in one 
setting at a time25. Between 2005 and 2011, the number of 
people on MMT in Dublin increased from 6906 to 7594. 
The proportion of patients aged over 34 years increased 
from 27% in 2005 to 54% in 2011.
In Ireland, the most stable patients are treated by their 
primary care physician in the community. Less stable 
patients, and people earlier in their treatment, are treated 
in multidisciplinary clinics. There is transfer of patients 
between these treatment settings as their needs change. 
The National Drug Treatment Centre (NDTC) is the 
longest established addiction treatment centre in Dublin. 
It caters for the least stable patients, the homeless and 
those with greatest co-existing needs26. Consequently, 
patients attending the NDTC frequently have increased 
medical, mental health and social needs compared to the 
wider patient group on MMT27. 
The NDTC is a psychiatry-led outpatient service with 
input from other professionals including nurses, coun-
sellors, social workers, outreach staff and a psychologist. 
The approach to treatment and patient outcome at this 
centre has previously been described27. Patients typically 
provide one supervised urine sample each week for drug 
toxicology. As patients stabilise, they receive more take-
away doses of their medication. Viral screening is actively 
encouraged but only occurs with patient consent. Where 
patients are found to have HCV or HIV infection, these 
conditions are managed in collaboration with other 
specialist services. This often involves dispensing of 
medication such as ART in the NDTC. Directly observed 
therapy is available for these medications.
STUDY PROCEDURE
All patients who exit treatment in the NDTC have their 
route of departure recorded. Over the seven year period 
from February 2005 to February 2012 we identified all 
patients who had a route of exit recorded as ‘death’.
We used a case-control design. Both cases and controls 
were opiate-dependant individuals maintained on 
Methadone. We sought controls by matching with cases 
on gender, age and treating team. We sought to identify 
a matching patient who was attending NDTC at the same 
time as the patient who died. Where there was no match-
ing patient with an age within 2 years of the index patient 
we extended the age range to 3 years, then to 4 years, 
and further if required. If more than one patient met the 
matching criteria, we randomly selected one. 
For cases and controls we examined the patients’ clinical 
notes to obtain information on their treatment, ongoing 
drug use, viral status, co-morbid illnesses, personal history 
and the cause of death. For controls, we assigned an index 
date to them which was the date of death of their matched 
case. We included the results of the urine drug screens 
in the month prior to death or prior to the index date, as 
appropriate. To confirm the cause of death, we used infor-
mation (where available) on each death from the National 
Drug-Related Deaths Index (NDRDI). The NDRDI is a 
census of all drug-related deaths in Ireland and is main-
tained by the Health Research Board. It records data from: 
the Coroner Service, the Hospital In-Patient Enquiry 
scheme, the Central Treatment List and the General 
Mortality Register via the Central Statistics Office20.
STATISTICAL ANALYSIS
Two levels of statistical analysis were conducted. First we 
examined the uni-variable association between risk of 
death and the following factors: age (yrs), gender, metha-
done dose (ml), drug use in the month proceeding death 
determined by urine drug screen (abstinent - all negative 
urine drug screens, occasional use – drug present in 1 to 3 
urine drug samples, regular use – was determined by all 4 
positive urine screens), history of imprisonment (yes, no), 
HIV status (positive, negative) and medical complications 
(yes, no).When examining the association with quantita-
tive variables which were normally distributed, we utilised 
the Student’s t test. Where quantitative variables were 
non-normally distributed, we utilised the Mann Whitney 
U Test. When examining categorical variables we used the 
chi square test, unless a predicted cell count was less than 
5 in which case we used Fisher’s Exact test. 
Secondly we also conducted a logistic regression analysis 
with dead/alive as the binary outcome variable. All covari-
ates were considered for entry into the final regression 
model. Covariates were removed when they were non-
significant and did not impact upon the predictive ability 
of the regression model. We calculated the Nagelkerke R 
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Square statistic to evaluate the goodness of fit of the model.
Previously it was demonstrated that 40% of patients 
at the NDTC were using cocaine28. An earlier study of 
methadone treatment at the NDTC found that the mean 
methadone dose was 74 mg (SD 25)26. Assuming the 
above we calculated that with 80 cases and controls we 
had 80% power to detect difference in methadone of 11 
mg, with p value set at 0.05. We also had 65% power to 
detect a 20% difference in rate of cocaine use.
RESULTS
There were 80 deaths over the seven years period. The 
mean number of patients on MMT in the NDTC during 
this period was 500. The mortality rate was 23 deaths per 
1000 person-years of treatment (95% CI = 18-28 deaths 
per 1000 years of treatment). 
Among both cases and controls, the median age was 35 
years (Inter-quartile Range [IQR] 30-41, range 21-55). 
Females accounted for 31% of deaths. In cases, the 
median methadone dose was 70 mg (IQR 55-90), while 
in controls it was 80 mg (IQR 60-90), but this difference 
was not statistically significant (Mann Whitney U Test, 
p=0.6). Additional characteristics of those who died and 
the control group are provided in Table 1.
There was no evidence that cases differed from controls 
in terms of recent use of heroin, cocaine or benzodi-
azepines. There was no significant difference between 
groups regarding co-morbid psychiatric illness or treat-
ment with psychotropic medication.
Cases underwent more frequent medical/psychiatric 
reviews than controls (Mann Whitney U Test, p=0.03). 
Cases were more likely to have a history of imprisonment, 
HIV infection and other non-HIV related medical prob-
lems. They were also more likely to have not been attend-
ing the clinic for treatment for at least one week immedi-
ately prior to death. Of the 18 patients who died and who 
were not attending the clinic for at least one week prior to 
death, eight were known to have been in hospital. 
Multivariable logistic regression indicated that the factors 
independently associated with increased risk of death 
were: history of imprisonment, non-attendance at the 
clinic for at least one week and presence of a co-morbid 
(non-HIV and non-HCV) medical condition (Table 2). 
HIV status was not associated with risk of death. The 
Nagelkerke R Square statistic for the regression model 
was 0.44, indicating that 44% of the variability can be 
explained by the model. 
CAUSE OF DEATH
Three broad categories of deaths were identified: poison-
ing, trauma and medical (Table 3). Poisoning deaths 
included all drug overdoses (accidental and intentional); 
Examples of death by trauma included homicide, and 
those due to road traffic accidents, while examples of 
deaths from a medical cause are those due to infections, 
emboli, and organ failure. For 67 (84%) deaths there was 
a record of the category of death in the clinical notes and 
also from the NDRDI. The category of death recorded in 
the clinical notes matched that in the NDRDI in almost 
all cases (63 [94%] of the 67 cases). In the four discrep-
ant cases, we used the NDRDI category when determin-
ing the final consensus-based category. In view of the 
demonstrated accuracy of the clinical notes, we used the 
category of death identified in those notes to attribute a 
category of death to those individuals who had no infor-
mation recorded in the NDRDI. This process allowed us 
to assign a category of death in 77 of the 80 cases. 
None of the poisoning deaths were determined to be a 
suicide, with a verdict of death by misadventure being 
recorded in 32 of 33 cases. 
The most common cause of medical death was infection, 
occurring in 10 of the 23 cases. 
POISONING DEATHS VERSUS OTHER 
DEATHS
Those who died by poisoning were younger than those 
who died from a medical illness (mean 34.2 [sd 6.6] years 
versus 41.3 [sd 7.5] years, p<0.001, independent sample t 
test), but were of a similar age to those who died of trau-
ma. They had been on a slightly higher methadone dose 
(median 8 0mg [IQR 60-90] versus Median 65 mg [IQR 
45-90], p=0.38) and demonstrated slightly increased 
heroin use but these differences were not statistically 
significant. They did not differ in terms of gender, medi-
cal or psychiatric history or prescription of psychotropic 
medication. There was no difference in terms of home-
lessness or history of imprisonment.
POISONING DEATHS VERSUS CONTROL 
GROUP
Compared to their age and gender-matched control group, 
cases who died by poisoning were more likely to be HIV 
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positive (29% versus 8%, p=0.02), more likely to have missed 
at least one week of treatment (17% versus 3%, p=0.05 
[Fisher test]), to have a history of imprisonment (76% versus 
41%, p=0.002), to have a history of homelessness (51% versus 
27%, p=0.03), and to have a history of current medical prob-
lems other than HIV/HCV (43% versus 11%, p=0.002). 
Cases who died by poisoning did not differ by HCV status, 
psychotropic medication, co-morbid psychiatric diagno-
sis, alcohol abuse or use of heroin, cocaine or benzodiaz-
epines. They did not differ in terms of methadone dose 
(median 80mgs [IQR60-90] versus 75mgs [IQR65-90], 
Mann Whitney U Test, p=0.7), or in terms of ‘take-away’ 
doses per week.
DISCUSSION
We found that the mortality rate among drug users on 
MMT in NDTC was 23 per 1000 person-years. In other 
recent studies of those on MMT, the mortality rate varied 
from 11.821 to 34.215 per 1000 person-years. 
Half of the deaths were due to poisoning, one third were 
due to medical causes and one sixth due to trauma. The 
profile of deaths was similar to that observed in other 
MMT groups, with overdose being recognised as the major 
cause of death7,16. It is also the main cause of death among 
those who leave MMT8. Opiate dependence is a risk factor 
for suicide, suicide attempts, and fatal and non-fatal acci-
dental overdose29. The number of suicides in this study 
may be under-recorded, particularly for deaths involving 
poisoning, where coroners record a verdict of “accident/
misadventure”30 or other narrative cause.
Despite the previous reports of increased mortality 
among those on low or very high methadone doses, this 
study did not find a relationship between methadone 
dose and mortality. The vast majority of patients in the 
NDTC was on methadone doses within the advised thera-
peutic range of 60-120 mg daily31.
We found no relationship between death and ongoing 
problem drug use in this study. Previous research in 
Ireland and elsewhere has indicated poorer outcomes 
amongst those with problem cocaine use19,28. 
The prevalence of co-morbid psychiatric disorder was high 
and similar in cases and controls. Rates of prescribing 
of psychotropic medication were similar in both groups 
also. Although other studies have found that psychiatric 
co-morbidity is associated with increased mortality3,13, 
prescription of antidepressants and antipsychotics have 
been found to be associated with decreased risk of death13. 
There is a substantial literature stating that recent release 
from prison is a risk factor for premature death. The great-
est risk of death is reported to be within the first two 
weeks after release due to reduced tolerance and subse-
quent accidental overdose18,32. Our study looked at impact 
of criminality from a different perspective. We found 
that cases were more likely to have a lifetime history of 
imprisonment compared to controls. This observation 
cannot be attributed to a short-term reduction in opioid 
tolerance. It may be that past imprisonment is a marker 
for a more chaotic lifestyle, higher impulsivity, greater 
involvement in crime and more exposure to dangerous 
situations. The standardized mortality ratios (SMRs) 
among ex-prisoners were reported to be elevated up to a 
decade after release from custody. The high rates of diseas-
es33, problem drug use and blood-borne viruses34 may 
reflect the fact that people who have been in prison are 
among the most disadvantaged groups within society33,35.
We observed that recent non-attendance for MMT was 
significantly higher among cases. Exit from treatment, 
especially if unplanned, is likely to bring with it a reduc-
tion in opioid tolerance and an escalation in heroin 
use18,36. Other studies have shown that disengagement 
from treatment and loss of continuity of care is signifi-
cant in increasing risk of death especially during the first 
weeks out of treatment7,37,38, with one study reporting 
that physicians had lost contact with only 8.3% of surviv-
ing patients but 30.4% of the deceased37.
We found that HIV infection was more prevalent amongst 
those who died, which is consistent with other studies 
of mortality16. While previous research in Dublin has 
reported a high prevalence of HCV and a relatively low 
prevalence of HIV among drug users39, in a recent study 
in England and Wales mortality rates due to HIV infec-
tion were observed to be 20 times higher among IDU 
compared with that in the general population40. While 
HCV infection was equally common in both the cases and 
controls, we found that the prevalence of current medi-
cal problems other than HIV/HCV was more common 
among cases. A similar observation of morbidity being 
associated with an increased risk of dying was made in 
other studies4,13. Given the fact that one third of deaths 
were due to medical illness, it is not surprising that there 
was an excess of medical illness among those who died. 
However, we also found that co-morbid medical illness 
was more common in those who died by poisoning 
compared to controls. This finding was unexpected; it 
may reflect an increased susceptibility to the respiratory 
depressant effect of opioids among the medically unwell. 
LIMITATIONS
The sample was recruited from a single specialist clinic 
in a single city and this may limit the generalizabil-
ity of our findings. We are aware of existing differences 
between regions, with Western Europe demonstrating 
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high mortality rates38. The current study also has modest 
power to examine the study hypotheses. We did not 
correct for multiple statistical tests and found factors 
significantly associated with mortality in the exploratory 
analysis, raising the possibility that some of these asso-
ciations may constitute type I statistical errors. However, 
Rothman has argued that conservative adjustments to 
the p value for multiple testing can result in a higher type 
II error rate, reduced power, and that it increases the 
likelihood of missing important findings41.
CONCLUSIONS
Our study has a number of practical implications. 
Treatment drop-out appears to be associated with 
increased risk of death, including a specific link with 
poisoning deaths. Patients on MMT should be warned 
that they face an increased risk of death, and in particular 
of accidental poisoning if they drop out of treatment. 
Patients who miss even a small number of days at a clinic 
should be followed up early and pro-actively by treatment 
providers. Former prisoners should also be recognised as 
a group with increased risk of premature death and may 
need closer monitoring. Prevention and early treatment 
of the medical complications of drug use may reduce 
mortality among MMT users. Therefore, when patients 
do have a current medical illness, clinicians should give 
appropriate harm reduction messages as such individu-
als may be more vulnerable to accidental overdose.
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TABLE 1. Characteristics of 80 people who died while on MMT, compared to 80 controls
Cases Controls
n (%) n (%) P Value
Gender
Male 55 (69) 55 (69)
Female 25 (31) 25 (31) 1.0
Age 
Under 30yo 16 (27) 13 (16)
30-39 37 (46) 43 (54)
40-49 18 (22) 16 (20)
50 and over 9 (11) 8 (10) 0.44
Daily Methadone Dose
Under 60mgs 20 (26) 15 (19)
60 to 120 mgs 55 (71) 64 (80)
Over 120mgs 2 (3) 1 (1) 0.43
Past Month Drug Use - based on urine drug screens
Opiates
abstinent 26 (32) 28 (35)
Occasional^ opiate misuse 32 (40) 30 (37)
Regular^ opiate misuse 22 (27) 22 (27) 0.93
Cocaine
abstinent 61 (76) 65 (81)
Occasional^ cocaine misuse 12 (15) 10 (12)
Regular^ cocaine misuse 7 (9) 5 (6) 0.72
Benzodiazepines
abstinent 8 (10) 8 (10)
Occasional^ benzo misuse 7 (9) 13 (16)
Regular^ benzo misuse 65 (81) 59 (74) 0.35
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Prison Ever 57 (71) 28 (35) <0.001
Homelessness Ever 33 (41) 24 (30) 0.14
Not attending for at least one week prior to death 18 (23) 1 (1) <0.001
Comorbid Psychiatric Disorder 50 (62) 45 (56) 0.42
Alcohol Abuse or Dependence 21 (27) 14 (17) 0.18
Prescribed Psychotropic medication
None 26 (32) 26 (32) 1.0
Non-Benzo Hypnotic only 8 (10) 6 (7) 0.58
Other psychotropic medication apart from 
Non-Benzo Hypnotic only
46 (57) 48 (60) 0.75
Prescribed Benzodiazepine 22 (27) 20 (25) 0.72
Prescribed any antidepressant 29 (36) 24 (30) 0.40
Prescribed Olanzapine 19 (24) 20 (25) 0.84
Medical problems
HIV positive 23 (29) 10 (12) 0.01
HCV antibody positive 50 (62) 53 (66) 0.62
Other medical problems noted 38 (47) 13 (16) <0.001
Epilepsy/Seizures 8 (10) 2 (2) 0.05
DVT 6 (7) 4 (5) 0.51
Cirrhosis or Liver Failure 9 (12) 2 (2) 0.03
On Anti-retroviral medication in NDTC 10 (12) 9 (11) 0.80
Clinic Attendance
Daily attendee 43 (54) 44 (56)
Has some take-away medication days each 
week
37 (46) 35 (44) 0.81
^“Occasional use” indicates that some but not all of the four urine screens tested positive. “Regular use” indicates that all of the four urine screens 
tested positive.
TABLE 2. Logistic Regression analysis of factors associated with increased risk of death among patients on 
MMT.
Adjusted Odds  
Ratio (AOR)
95% CI AOR P value
History on Imprisonment 4.6 (2.0-10.1) <0.001
Current non-HIV & non-HCV related medical illness 5.3 (2.2-12.6) <0.001
Not attending for at least one week prior to death 19.2 (2.3-160) 0.006
HIV Status
Negative 1.0
Positive 2.2 (0.8-5.7) 0.11
Not known 8.8 (0.9-90) 0.06
TABLE 3. Causes of death of 80 Patients who died while on MMT 2005-2011.
n (%)
Cause of death indicated by the medical notes^
Poisoning 34 (46)
Medical 26 (35)
Trauma 14 (19)
Medical notes suggest suicide^ 8 (11)
TABLE 1. Characteristics of 80 people who died while on MMT, compared to 80 controls (continued)
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NDRDI Information (n=71)
Company at time of death (n=68)
Alone 26 (38)
Medical personnel 23 (29)
Partner/Family/Friends 18 (26)
Place of major incident (n=68)
Private Dwelling 23 (34)
Hospital 23 (34)
Accommodation for the homeless 12 (18)
Public place 9 (13)
Other 1 (1)
Type of death according to NDRDI
Poisoning 34 (49)
Medical 23 (33)
Trauma 13 (19)
Coroner’s Verdict (n=60)
Misadventure 38 (63)
Narrative 8 (13)
Undetermined 3 (5)
Natural 5 (8)
Homicide, Accident, Suicide 6 (10)
Consensus cause of death based upon NDRDI & Clinical notes (n=77)
Poisoning 37 (48)
Medical 27 (35)
Trauma 13 (17)
^It was impossible to ascertain a potential cause of death from the medical notes in 6 cases
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Creation of a Miniature Black Market with Use of Gift Cards 
For Research Participation in an Addicted Population
Susan Finch MD, CM, FRCP(C)1, Markus Kuksis MSc2, Cynthia DiProspero BA2 
TO THE EDITOR:
Clinical wisdom suggests that patients with Substance 
Use Disorders (SUD) are at higher risk for increased 
substance use or relapse when money is readily available. 
Patients with SUD often describe using substances until 
money runs out and some have a history of spending 
large cash payments on drugs over a short period of time. 
Ethical concerns have been raised regarding use of cash 
incentives, particularly sizeable amounts, for research 
participation in SUD populations1,2. Monetary incentives 
may increase substance use, increase risk of relapse and 
increase perceived coercion1,2. However, the contingency 
management literature suggests that incentives are effec-
tive in promoting a variety of target behaviours in SUD 
populations3,4,5. Studies by Higgins et al.3 and Petry et 
al.4,5 show incentives of low monetary value, vouchers, 
and even a chance of reward can be effective.
When designing our research study, we felt that an incen-
tive for participation was very important to promote 
recruitment. Our research project was an exploration 
of the relationship between the severity of trauma, 
Posttraumatic Stress Disorder (PTSD) symptoms and 
SUD in patients seeking outpatient treatment for SUD. 
Participants were recruited from several clinics and 
completed a variety of self-report questionnaires and 
study questions which took no longer than 60 minutes. 
Upon completion of the questionnaires, each partici-
pant received a $10 gift card to a well known, popular and 
widely distributed coffee shop that we suspect the study 
population frequented. Gift cards were used to avoid 
cash payments due to the concern that cash incentive 
would lead to the procurement and the use of substanc-
es. A small dollar amount was chosen to avoid coercion. 
In spite of these precautions, at one site we indirectly 
observed an interesting phenomenon.
One of the recruitment sites was a street based store front 
agency and methadone clinic with a mandate to serve 
intravenous drug users, people recently released from 
incarceration, homeless people, and sex trade workers. 
At this site, it was reported back to the research team by 
the clinic staff that clients who had participated in the 
study were selling their $10 gift cards to another 2 clients 
for $8 cash. A brisk business occurred, and gift cards sold 
at a loss were able to fund food expenses for the 2 clients 
on a road trip to the East Coast.
This ‘miniature black market’ was unexpected and only 
discovered indirectly so we were not set up to measure 
it. However, it is an interesting observation that suggests 
that cash incentives are preferred, even if the amount 
is low or at a loss, for street involved substance abusing 
populations. Additionally, it suggests that participants 
may alter methodology, particularly the form of incen-
tive, unbeknownst to investigators and despite careful 
study design. Thankfully, Festinger et al. 1,2 have shown in 
2 studies that neither the amount nor the mode of incen-
tive (cash vs. gift card) was associated with increased 
substance use or perceived coercion, and that cash 
incentives and higher dollar amounts were associated 
with increased participation in research studies.
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BOOK REVIEW: Diagnosing and Treating Addictions 
An Integrated Approach to Substance Use Disorders and 
Concurrent Disorders
Dr Merville Vincent • Edgewood Publishing 2014 • Review By: Adam Quastel MDCM, FRCPC 
Books on professional subjects aimed at the non-expert 
audience are always a bit tricky: leaning to technical and 
professional parlance might appease colleagues but you 
lose any intended general audience; veering too far to 
accessible  generalities, on the other hand, may  render 
the project unsatisfying  as a vehicle of knowledge 
translation. 
Diagnosing and Treating Addictions attempts this balanc-
ing act in offering a general overview of the field of addic-
tion. This brief soft cover text is a readable and approach-
able introduction to Addiction Disorders presented by 
Merville Vincent, a psychiatrist at Edgewood treatment 
Centre in British Columbia which also acts as the books 
publisher.  Beginning with accessible introductory chap-
ters on causation, pharmacology of addiction and diagno-
ses, Dr. Vincent takes the reader through some very read-
able discussions of treatments, and concurrent disorders 
offering case histories along the way for emphasis.  
In opening with a thoughtful personnel account of his 
own journey as a professional into this field, Dr. Vincent 
sets the tone from the outset as an approachable account 
of the field aimed at the non-expert reader.  That the text 
is published by Edgewood itself suggests that the project 
may have been born of an internal need to provide an 
informative text for patient and families.
Inevitably, this is the most attractive aspect of this text: 
its natural structure and approachable voice allowing the 
non-expert access to this difficult and confusing field. That 
said, it appears to have been written with a fairly educated 
audience in mind, as reasonably complex and referenced 
explanations abound. In fact, Vincent seems at his best 
when he provides a brief, yet professional summary of 
trauma and its treatment as part of his journey through 
the various psychiatric diagnoses and their importance in 
addictions. 
But like every text, there is a perspective here.  Perhaps 
the biggest issue worthy of comment are the references 
to the more medicalised aspects of addiction care. When 
describing the role of the Edgewood facility in tapering 
methadone, for instance, Vincent bypasses the extant 
data indicating the high relapse rates associated with 
quick methadone taper. Regardless of the individual clini-
cal need addressed in the text, discussion of the larger 
issues involved with methadone and opiate care could 
help understand the context of the role of a residential 
treatment facility in opiate agonist treatment. 
Similarly, in reviewing benzodiazepine treatment of alco-
hol withdrawal, Vincent describes fixed dosing and symp-
tom triggered dosing options, and later indicates that his 
own treatment facility’s protocols severely limit benzodi-
azepine use; this seems to me, at least as described in this 
text,  to limit the CIWA  and it was disappointing  that there 
was not further discussion of how this would be  managed 
in the facility. Again, he indicates clinicians have been 
skeptical of anti-craving medication, naltrexone and acam-
prosate, but without an overview of the issues involved (or 
the extensive positive research in this area  that I personally 
think is very helpful to patients and families suffering from 
alcoholism)   it may be difficult to situate and understand 
the slow uptake of these interventions. 
Mainstream Addiction Medicine practice in Canada has 
supported these biomedical interventions so divergent 
opinion could make for interesting debate.  In turn, non-
experts who are positioned outside these discussions 
could benefit from an overview of perspectives. In this 
sense, it’s a pity that these issues are not given more space: 
after all, we have all been set back in this field by the 
uncomfortable standoff between conventional psychiat-
ric, medical and community addiction treatments even as 
we are moving towards increasingly integrated models of 
care. Balanced comprehensive discussions of what have 
sometimes been presented as opposing models of care are 
very much needed.  Dr. Vincent does much to provide an 
integrated overview in many respects and for this deserves 
credit:  it’s these missing elements, however, that just may 
be the way forward. 
Adam Quastel MDCM, FRCPC 
Addictions Lead, St Michael’s Hospital Mental Health and  
Addictions Service Assistant Professor, University of Toronto
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BRAIN PLASTICITY AND ADDICTION
Bryan Kolb (kolb@uleth.ca)
Professor Neuroscience, University of Lethbridge
Brain plasticity refers to the brain’s ability to change in 
response to experiences to provide a mechanism for 
adaptive change. But such adaptations are not always 
beneficial. Addictions are chronic relapsing disorders 
caused by genetic, epigenetic, and environmental factors 
that interact to lead to long-lasting experience-induced 
changes in certain brain regions in vulnerable individu-
als. I will review the types of plastic changes, including 
molecular, cellular, and behavioral changes, that occur 
in specific brain regions, including the prefrontal cortex, 
striatum, and brainstem, to mediate behavioral changes in 
addiction. But addiction is not about one brain system but 
rather involves multiple brain systems that support differ-
ent types of behavioral changes and lead to more than one 
type of addiction. The plastic changes in addiction are 
not novel but are seen in many other types of behavioral 
change including learning and memory, which helps to 
provide a key to understanding how they occur. A signifi-
cant challenge is in understanding why some people are 
more vulnerable than others. A promising direction is in 
the study of epigenetic differences underlying susceptibili-
ty that may span generations. Finally, there are metaplastic 
changes (interactions among plastic changes) that provide 
explanations for why addiction-related plasticity can influ-
ence other behaviors such as learning and memory.
OPIOID AND METHANDONE
FACTORS IMPACTING TREATMENT 
RETENTION FOR PATIENTS WITH 
OPIOID-DEPENDENCE IN NORTHERN 
AND RURAL REGIONS OF ONTARIO
Kathleen Anderson (kanderson@nosm.ca) 
Northern Ontario School of Medicine, Sudbury ON
Background: For patients with opioid dependence in 
Northern Ontario, the interplay between access to mental 
health services and methadone maintenance therapy is 
complex. Psychiatric comorbidity including mood, anxi-
ety, personality and post-traumatic stress disorders, are 
common with opioid dependence. Research indicates 
a greater compliance with treatment if it is provided 
by the same physician or at the same facility in an inte-
grated service. A second line option includes working 
with psychiatric services to establish a referral process and 
frameworks for shared care. While an integrated approach 
is optimal, patients living in Northern, rural, and remote 
regions of Ontario have limited access to psychiatric care 
and methadone programming; as a result, mental health 
and opioid-dependence are treated separately. Objective: 
Identify factors which contribute to positive treatment 
outcomes for patients with opioid dependence and comor-
bid mental health disorders. Methods: Using health data 
from Ontario, we conduct a retrospective cohort analysis 
on patients with diagnosed mental health disorders who 
are also enrolled in methadone maintenance therapy. One 
year of continuous methadone therapy is the primary 
treatment outcome. Results: Preliminary analysis indicates 
that a patient’s geographic status (e.g., northern, urban, 
rural) and treatment modality (in person vs. telehealth) 
have an impact on treatment outcomes. Further study into 
the contribution of methadone (or Suboxone) will also be 
discussed. Conclusions: Factors which contribute to posi-
tive treatment outcomes can be integrated into treatment 
strategies for patients with opioid dependence and comor-
bid mental health disorders in small urban, rural, remote 
and underserviced regions such as Northern Ontario.
Literature references:
1. Guidelines for the Psychosocially Assisted Pharmacological 
Treatment of Opioid Dependence, World Health 
Organization, 2009
METHADONE-ANTIPSYCHOTIC DRUG 
INTERACTIONS: A SYSTEMATIC REVIEW 
OF THE LITERATURE
Natalia Ng and Rita Watterson (rwatter@ucalgary.ca) 
University of Calgary
Opioid use is a common clinical problem in the field of 
substance use disorders. Over the past decade, the use of 
methadone has been shown to be an effective treatment in 
managing opioid dependence. Often however, psychiatric 
patients on methadone treatment are concomitantly taking 
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antipsychotics to manage a variety of issues. Methadone-
antipsychotic interactions (MAI) have been shown to cause 
several adverse effects and can impact quality of life. 
Two psychiatric investigators and a clinical librarian 
conducted a systematic review of published literature in 
MEDLINE, EMBASE, PsycINFO, PubMed, CINAHL, and 
Web of Science.
Upon entering in all the search criteria, 67 articles were 
generated. Of the 67 articles, a total of 7 articles were 
yielded.
Two consistent themes were found amongst the selected 
literature: 1) Atypical antipsychotic use, specifically 
quetiapine, in conjunction with methadone manage-
ment, has been shown to increase methadone levels in 
opioid-dependent users. This increase has been shown to 
increase the risk of opioid withdrawal symptoms, as well 
as cardiac effects. Risperidone was shown to accelerate 
methadone metabolism, thus precipitating opioid with-
drawal symptoms. 2) Typical antipsychotic use, specifi-
cally chlorpromazine with methadone, has been shown 
to cause central nervous system (CNS) and respiratory 
depression. The literature also revealed an increased risk 
of QTc prolongation in haloperidol-methadone users.
These findings highlight the importance of ongoing 
clinical monitoring for those managed concomitantly 
on methadone and antipsychotics, particularly quetiap-
ine, risperidone, chlorpromazine, and haloperidol. 
Monitoring may include obtaining an electrocardiogram 
at baseline, as well as thorough monitoring of respiratory 
depression or withdrawal symptoms. 
Literature references:
1. Lee HY, Li JH,  Wu LT,  Wu JS,  Yen CF,  Tang HP. Survey of 
methadone-drug interactions among patients of methadone 
maintenance treatment program in Taiwan. Substance Abuse 
Treatment, Prevention, & Policy. 2012; 7:11.
2. Grabowski J,  Rhoades H,  Stotts A,  Cowan K,  Kopecky C,  
Dougherty A,  Moeller FG,  Hassan S,  Schmitz J.  Agonist-
like or antagonist-like treatment for cocaine dependence 
with methadone for heroin dependence: two double-blind 
randomized clinical trials. Neuropsychopharmacology. 2004; 
29(5):969-81.
FOSTERING RESILIENCY AND 
PSYCHOSOCIAL STRATEGIES TO 
SUPPORT OPIOID ELIMINATION 
Elizabeth Saxton (esaxton@orionhealth.ca)
OrionHealth rehabilitation and Assessment Centres, Calgary AB
Objective: To demonstrate the value of fostering resil-
iency and psychosocial coping in opioid elimination and 
abstinence. 
Methods: Individuals who have chronic pain may take 
opioid medications as part of their treatment regime. 
There is a certain group of clients who do not experience 
a significant increase in functioning or reduction in pain 
to warrant continuing opioid therapy. They may also 
experience side effects, display high risk for misuse, or are 
prohibited from taking such medications at their work. 
The goals of our interdisciplinary medication manage-
ment programs are to: 
· Execute an opioid taper protocol for each client 
· Improve mood 
· Educate on medications, their uses and side effects 
and, in so doing, change client attitudes and beliefs 
about pain and medication use 
· Integrate psychosocial skills for functional goal 
attainment and fostering of resiliency 
The program is typically 4 to 8 weeks. Key interventions in 
our program include goal setting, behavioural activation, 
empowerment, active participation, reduction of fear 
avoidance behaviours through exposure and increased 
self-efficacy. In daily programming, they practice pain 
self-management and recognize, through didactic expe-
riences, that they are able to manage without opioids. 
Results: A number of outcome measures are used to 
evaluate the medication management program includ-
ing a measure of depressive symptoms (BDI – II) and 
sustainability of that taper after the program. 93% of 
participants eliminate opioids, 78% sustain elimination 
at 3 months, 86% of participants have same or better 
mood after elimination. 
Conclusion: An opioid reduction program, emphasizing 
psychosocial skills and resiliency, continues to demon-
strate positive outcomes for clients. 
Literature references: 
1. Grattan A, Sullivan M, Saunders K, Campbell C, Van Korff M. 
Depression and Prescription Opioid Misuse Among Chronic 
Opioid Therapy Recipients With No History of Substance 
Abuse. Annals of Family Medicine 2012; 10 (4), 304 – 311.
DEVELOPING A METHADONE 
INFORMATION HANDBOOK: THE 
PATIENT’S PERSPECTIVE
Alison Turnquist (aliturnquist@gmail.com) 
University of Saskatchewan
Methods/Methodology: Three focus groups (n = 18) were 
guided in discussion through semi-structured interviews 
to explore the objectives of the study. Audio recordings 
were transcribed verbatim and analyzed for themes. 
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Demographic data including age, gender, education, 
work, ethnicity, and time spent on MMT was collected. 
Findings were discussed with methadone-prescribing 
physicians, addiction counselors, and pharmacists for 
further input into the design of the handbook.
Results/Findings: Four themes were identified. Theme 
one, Understanding Methadone, included defining 
methadone, and identifying benefits and harms of 
methadone. Theme two, Lack of Information, discussed 
initial sources of information, current sources of infor-
mation, and a desire for more resources. Theme three, 
Handbook Desirability, centered on assessing the 
content and artwork of a sample handbook provided. All 
groups reached consensus that they desired a handbook. 
Theme four, Stigma and Prejudice, included spontane-
ous conversation about difficulties in dealing with the 
stigma of using methadone treatment, particularly in 
the context of pharmacy interactions.
Conclusion and Recommendations: As a result of the 
findings that participants felt they lacked adequate 
resources and desired more information, including an 
information handbook, the development of a patient-
centered handbook was initiated using the recommen-
dations provided by participants. 
CARE DELIVERY
PATIENT AND PRISON-SETTING FACTORS 
AFFECTING MEDICATION ADHERENCE 
IN CORRECTIONAL FACILITIES: A SHINE 
MIXED METHODS STUDY
Lauren Cuthbertson (lauren.cuthbertson@ucalgary.ca) 
University of Calgary, Calgary AB
Objective: To explore patient and prison-setting factors 
affecting medication adherence from the perspective of 
inmates at the Calgary Remand Centre (CRC) to develop 
recommendations for medication administration in 
correctional facilities and increase student-physician 
sensitivity to the needs of marginalized and vulnerable 
populations.   
Methods: A mixed methods study using clinical records, 
structured questionnaires and qualitative interviews was 
used. The study gathered information on participant 
demographics, general health information and substance 
use history, medication information, prison-setting 
barriers/facilitators, and individual barriers/facilitators 
to medication adherence. All inmates at CRC are over 
18; the majority are male and many report substance use 
disorders. The inclusion criteria for the study included 
inmates that had 1 or more incidents of medication non-
adherence since their admission to the CRC.
Results: At the individual level, medication adherence is 
influenced by personal insight into disease and medica-
tion management, inmate social support, and perceived 
frequency of side effects. At the institutional level, rigid 
schedules for inmate activity and attitudes of health-
care providers towards inmates affected medication 
adherence. This combination of factors perpetuates the 
knowledge gap between physicians/student-physicians 
and their vulnerable patients in the prison-setting ulti-
mately affecting medication adherence.
Conclusion: Effective medication administration within 
prisons is important to manage inmates’ symptoms, stop 
relapse, slow disease, and help recovery. Both individual 
and institutional barriers to medication adherence in 
correctional facilities hinder effective disease manage-
ment. Findings of this study inform recommendations 
to improve disease management in correctional facilities, 
and may have relevance for medication management of 
other vulnerable populations outside of the prison-setting. 
Literature references:
1. Blanco JM, Pérez IR, March JC. Adherence to antiretroviral 
therapy among HIV-infected prison inmates (Spain) Int J 
STD AIDS. 2005; Feb16(2):133-8.
2. Martin RE, Buxton JA, Smith M, Hislop TG. The scope of 
the problem: The health of incarcerated women in BC. BC 
Medical Journal. 2012 Dec;54(10):502-508.
THE ADDICTION RECOVERY AND 
COMMUNITY HEALTH (ARCH) TEAM: 
MEETING THE NEEDS OF SOCIALLY 
COMPLEX PATIENTS WITH SUBSTANCE 
USE DISORDERS IN AN ACUTE CARE 
SETTING
Ginetta Salvalaggio (ginetta@ualberta.ca) 
University of Alberta, Edmonton AB
An acute care hospital serves an important role as a 
societal safety net; for some complex inner city patients 
the hospital is often the only 24/7 safe place to access 
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medical care and services. As a critical point of access, 
acute care settings must be prepared to offer, in addition 
to acute medical interventions, evidence-based addic-
tions treatment and social stabilization. The feasibility 
of traditional addiction treatment approaches for inner 
city patients, however, is complicated by complex social 
circumstances; evidence-based treatments and resources 
must be considered in the overall context of the chal-
lenges and strengths faced by each individual patient. 
Addiction Recovery and Community Health (ARCH) is 
a multidisciplinary consult team embedded within an 
inner city acute care hospital. With relationship-building 
as a core principle, addiction stabilization activities are 
complemented by social stabilization, health promo-
tion, community linkage, and harm reduction activities. 
Launched in July 2014, ARCH sees approximately 20 new 
consults weekly. A process evaluation is underway to 
understand patient and other stakeholder experiences 
with the team. Consenting patients are also being tracked 
longitudinally in a controlled study to determine ARCH’s 
impact on substance use, health services use, health 
promotion outcomes, and social outcomes. ARCH’s 
clinical and research successes hinge on strong academic, 
health sector, social sector, and data custodian partner-
ships, however, the most critical partnership remains 
that between team members and the inner city commu-
nity it serves. We will discuss our experience with these 
partnerships and present preliminary patient outcomes. 
DIGGING A DEEPER HOLE
Sharon Koivu (Sharon.Koivu@lhsc.on.ca)
London Health Sciences Centre, London ON
Objective: Incidence and Deaths from Infectious 
Complications in Patients Suffering from Injection 
Prescription Opioids Addiction have increased since 
discontinuing OxyContin.
Study: Oxycodone was an effective analgesic but expo-
sure to it, even as a legal prescription, has been found to 
lead to a high incidence of abuse, addiction and death 
from overdose. Largely for this reason, OxyContin and its 
generic counterpart have been removed from the Ontario 
Drug Formulary.
Physician prescribing habits have largely turned to other 
opioid, particularly HydromorphContin. This has created 
unexpected collateral damage.
Result: We have found that since the discontinuation of 
OxyContin the incidence of infectious complications of 
injection drug abuse, including endocarditis, sepsis and 
death have increased dramatically.
We found that this is related to the physical properties 
of HydromorphContin as well as harm reduction kit use 
habits.
Conclusion: We need to learn from this when making 
future policies and practice changes.
Harm reduction kits and education, need to evolve with 
changing abuse patterns.
Physicians prescribing opioids need to keep informed 
about abuse patterns and their consequences.
Otherwise we could continue to dig a deeper hole.
THE DEVELOPMENT OF A CONCURRENT 
DISORDERS SERVICE
Jennifer Brasch (jennbrasch@cogeco.ca)
St. Joseph’s Healthcare, Hamilton ON
Patients with co-occurring addictions and mental illness 
are often unable to achieve recovery in standard addiction 
services. St. Joseph’s Healthcare Hamilton determined 
that patients with concurrent disorders (CD) comprised 
50% of their acute inpatient population and had high 
rates of repeat admissions and emergency room visits.  A 
Concurrent Disorders Service was developed to address 
the care needs of this high-morbidity group.  Developed 
in stages, the initial phase began with converting one of 
Hamilton’s 4 acute inpatient psychiatry units to serve 
patients with concurrent disorders.  The unit is still for 
patients requiring an acute psychiatric admission, but now 
provides comprehensive assessments for addictions, as well 
as individual and group counselling using a harm reduc-
tion framework.  Next, we created a Concurrent Disorders 
Outpatient Clinic with one team providing both psychiat-
ric care and addictions counselling.  A service review found 
that 13 patients admitted to the CD inpatient unit who 
then received CD outpatient care averaged 3.46 ER visits 
each in the year before admission, and 0.38 visits in the 
year after. We are now developing the Capacity Building 
Team, which works with mental health outpatient clinics 
and inpatient units to improve the staff’s knowledge and 
skills in assessing and treating addictions in their patients. 
The presentation will focus on the development of the 
Service, implementation, outcome measures, successes 
and challenges, as well as plans for the future.
Literature references:
1. Sterling S, Chi F, Hinman A. Integrating care for people with 
co-occurring alcohol and other drug, medical and mental 
health conditions (Review). Alcohol Health & Research 
World 2011; 33(4):338-49.
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BLENDING ABORIGINAL AND 
WESTERN HEALING METHODS TO 
TREAT INTERGENERATIONAL TRAUMA 
WITH SUBSTANCE USE DISORDER IN 
ABORIGINAL PEOPLES WHO LIVE IN 
NORTHEASTERN ONTARIO CANADA
Teresa Naseba Marsh (thunzi@me.com) 
Laurentian University, Sudbury ON
Background: As with many Indigenous groups around 
the world, Aboriginal communities in Canada face 
significant challenges with trauma and substance use. 
The complexity of symptoms that accompany intergen-
erational trauma and substance use disorders represents 
major challenges in the treatment of both disorders. 
There appears to be strong evidence that strengthen-
ing cultural identity, incorporating traditional healing 
practices, community integration, and political empow-
erment can enhance and improve mental health and 
substance use disorders in Aboriginal populations. 
Methods: This study explored the feasibility of utilizing 
an empirically studied treatment model, Seeking Safety 
(2002a), and incorporating Indigenous traditional healing 
practices for the treatment of intergenerational trauma 
and substance use disorders. This mixed-method inquiry 
incorporated a 13-week Seeking Safety Sharing Circles 
program with 24 Aboriginal peoples in Northern Ontario. 
Data was collected from Sharing Circle sessions, semi-
structured interviews, the Trauma Symptom Checklist-40, 
Addiction Severity Index (Lite), and the Historical Loss 
Scale & Historical Losses Associated Symptom Scale.
Results: Results revealed decreased substance use 
and trauma symptoms, supporting the benefits of the 
combined model to enhance healing. Furthermore, 
Sharing Circles and the presence of Elders and Aboriginal 
helpers increased the benefits of the blended model.
Conclusion: This study provided mental health and 
substance use interventions for institutions, Aboriginal 
communities, community leaders, stakeholders, and 
policy makers to help enhance Aboriginal wellness 
and bring healing for intergenerational trauma and 
substance use disorders.
Literature references:
1. Marsh TN, Coholic D, Cote-Meek S, Najavits LM, Blending 
Aboriginal and Western healing methods to treat 
intergenerational trauma with substance use disorder in 
Aboriginal peoples who live in northeastern Ontario Canada. 
Harm Reduction Journal 2015; 12 :14 (20 May)
EDUCATION
PROVINCIAL ADDICTION CURRICULA & 
EXPERIENTIAL SKILL (PACES) TRAINING 
INITIATIVE
Laura Calhoun, MD, FRCPC, MAL(H)
Question Support: Jill Mitchell/Tuxephoni Winsor RN.BN.MHS
Despite the prevalence and undeniable impacts of addic-
tion and mental health disorders, professional development 
activities addressing primary addiction and concurrent 
disorders remain elective, sporadic and undersubscribed 
when compared with other topics of academic instruction.
In response, Provincial Addiction & Mental Health, Alberta 
health Services is committed to the implementation of a 
provincially accessible curriculum that adheres to academic 
standards for accreditation, and provides for experiential 
skill training opportunities that meet the learning needs 
of intermediate and advanced practitioners responding to 
adult populations experiencing concurrent disorders. 
The Provincial Addiction Curricula and Experiential Skills 
(PACES) Training Initiative will utilize learning technol-
ogy in the development of a self-navigated, academic 
curriculum and simulated learning event. PACES seeks 
to enhance current service delivery by addressing a well-
documented gap in addiction education for medical and 
psychosocial practitioners. The PACES training initiative 
will evaluate success of its delivery in support of improv-
ing quality service and public assurance. 
Literature references:
1. Crockford & el-Guebaly, 2015; el-Guebaly & Violato, 2015; 
Wild, Wolfe, Wang & Ohinmaa, 2014; Wood, Samet, Volkow, 
2013; el-Guebaly & Violato, 2011; Crockford & el-Guebaly, 
2009; Urbanoski, Cairney, Bassani & Rush, 2008; Ewashen & 
Zaganelli, 2007.
DIVERSITY OF TRAINING HEALTHCARE 
PROVIDERS IN ADDICTION MEDICINE 
Jan Klimas (jan.klimas@ucd.ie)
BC Centre for Excellence in HIV/AIDS, Vancouver BC
Objectives: this rapid rise of new structured educational 
programmes for addiction medicine specialists isn’t with-
out problems. We describe a programme of research that 
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tries to understand mechanisms for scaling up and stan-
dardising the addiction medicine education internationally.
Methods: The project has three phases:
1. Scoping review of literature and interviews with alum-
ni of the Canadian addiction medicine fellowship.
2. Expert consultation and educational needs assess-
ment at both systems. 
3. Development and implementation of a Novel 
Addiction Medicine Education (NAME) curriculum 
for medical students and family physicians in Ireland.
Results: Early findings from the interviews with faculty 
and alumni of the St. Paul’s Hospital Goldcorp Addiction 
medicine fellowship (n=12) highlighted the key role 
of evidence-informed curricula and expansion of the 
current programmes to include other, non-physician 
health professionals. Participants experienced changes in 
the areas of knowledge, skills, attitudes, provider behav-
ior and patient outcomes. Organisational, structural, 
provider, patient and community factors hindered or 
fostered learning. Our scoping review of literature identi-
fied a high diversity in physician education on addiction 
that prevents comparative research and hinders advance-
ment of physician training. 
Conclusions: Recognising that diversity of the programmes 
reflects the critical role of responding to the regional needs 
and context in the development and implementation 
of these programmes, we call for standardised training 
programmes in addiction medicine internationally. 
Literature references:
1. Klimas J, Cullen W. Addressing a Training Gap through 
Addiction Research Education for Medical Students: Letter to 
editor.  Substance Abuse. 2015; 36(1):3-5
2. Ayu A P, et al. “Effectiveness and Organization of Addiction 
Medicine Training Across the Globe.”European Addiction 
Research 2015;21(5): 223-239.
3. O’Brien S and Cullen W. Cullen “Undergraduate medical 
education in substance use in Ireland: a review of the litera-
ture and discussion paper.” Irish Journal of Medical Science 
2011;180(4): 787-792.
4. el-Guebaly N, et al. “Medical education in substance-related 
disorders: components and outcome.” Addiction 2000;95(6): 
949-957.
5. Wood E, et al. “Physician education in addiction medicine.” 
JAMA 32013;10(16): 1673-1674.
ADDICTION PSYCHIATRY: THE CANADIAN 
JOURNEY
Nady el-Guebaly (nady.el-guebaly@albertahealthservices.ca)
University of Calgary
Objectives: The search for educational validation must 
follow national guidelines and be informed by an 
international yearning for standardization. An update on 
the ongoing Canadian journey is presented.
Method: Recent developments in training in addiction 
psychiatry is presented derived from:
a) Approaches to post graduate education in Canada 
(Levrette et al)
b) The PGY1 experience, 2014 update (Husarewycz et al)
c) Overview of clinical practices and general recom-
mendations (Fleury et al)
d) Updated curriculum guidelines (Crockford et al) 
Results: The above developments and the recent accep-
tance in principle by the Royal College of a Diploma in 
Addiction Medicine starting with Specialists resulting in 
increased awareness for the need of specialty training at 
all levels of medical education. Sharing our international 
experience as well as available products like the ISAM 
Certification exam and new Textbook are major boosters 
to national curricula.
A model for potential differentiation of levels of 
proficiency between Generalists and Specialists with 
Addiction Medicine will also be presented.
Conclusion: National educational initiatives require seiz-
ing opportunities presented by evolving guidelines as 
well as utilizing international experiences and products. 
Literature references:
1. Levrette JS, Hnatko GS, Persad E. Postgraduate education 
in psychiatry in Canada. Canadian Psychiatric Association, 
2009, pp 167-182.
2. El-Guebaly N, Carra G, Galanter M. Textbook of Addiction 
Treatment: International Perspectives, Springer, 2015, pp 
2397-2440.
QUALITATIVE ASSESSMENT OF 
COMMUNITY PHARMACISTS’ 
EDUCATIONAL AND SKILLS NEEDS 
CONCERNING ADDICTION
Sarah Fatani (sarah.fatani@usask.ca)
University of Saskatchewan
Objectives: Community Pharmacists are the most acces-
sible health care providers. However, pharmacists are 
poorly utilized when addressing the issue of substance 
abuse and addiction. It can be hypothesized that the 
lack of educational/training are the driving factor for 
such deficiency. Therefore, we aimed at 1) Evaluating 
the current educational curricula in pharmacy schools 
in Canada in relation to addiction; 2) Assessing pharma-
cists’ current skill set and the extent of the problem in the 
city of Saskatoon from their perspectives; 3) Identifying 
skills and educational needs for community pharmacists 
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concerning providing optimum services to drug addicts. 
Methodology: Firstly, an inquiry was sent 10 phar-
macy schools in Canada to apprehend the nature of the 
educational material taught about addiction. Secondly, 
semi-structured interviews was deemed most appro-
priate method. In order to recruit participants for the 
interviews and generate general understanding about 
pharmacists’ perspectives regarding addiction a survey 
was sent to all community pharmacists in Saskatoon. 
During interviews, pharmacists were asked to express 
their needs to provide optimum health care services 
for drug addicts. Results: School surveys revealed that 
addiction is rarely discussed as a social matter but 
primary from pharmacological endpoint, leaving new 
graduates ill-equipped to provide the right services to 
addicts. Respondents acknowledged that addiction is a 
major concern in the city of Saskatoon and that they are 
not trained to deal with drug addicts. Finally, two major 
issues emerged, namely “lack of knowledge” as well as 
the need for immediate and long-term educational/
training initiatives.  Implications: This work will influ-
ence future educational plans as well as provide sugges-
tions to improve the contemporary educational plans 
based on a view from the fields of practice
Literature references:
1. Lang K, Neil J, Wright J, Dell C A, Berenbaum S, El-Aneed 
A. Qualitative investigation of barriers to accessing care by 
people who inject drugs in Saskatoon, Canada: perspectives 
of service providers. Substance abuse treatment, prevention, 
and policy, 2013; 8(1), 1-11.
2. Lang K, et al. “Qualitative investigation of barriers to access-
ing care by people who inject drugs in Saskatoon, Canada: 
perspectives of service providers.” Health Care 2013;8: 24.
GAMBLING
LOW RISK GUIDELINES FOR GAMBLING 
DERIVED FROM LONGITUDINAL 
RESEARCH
Shawn Currie (shwan.currie@albertahealthservices.ca)
University of Calgary
Responsible gambling is promoted to prevent the devel-
opment of problem gambling but there is no quantitative 
definition of what responsible or “low-risk” gambling 
is in terms of gambling behaviour. In the field of alco-
hol research, low-risk drinking guidelines have been 
developed and widely disseminated to the public (e.g., 
maximum 2 drinks a day, 14 drinks per week). In light of 
the rapidly expanding gaming industry and significant 
rates of problem gambling in North America, the devel-
opment of comparable low-risk gambling guidelines 
has been recommended. To this end, a set of low-risk 
gambling limits were produced using Canadian epide-
miological data on the intensity of gambling behaviour 
and related consequences. The empirically derived limits 
(gambling no more than two to three times per month, 
spending no more than $501-$1000CAN per year or no 
more than 1% percent income on gambling) accurately 
predicted risk of gambling-related harm after control-
ling for other risk factors. A significant limitation of this 
research is the cross-sectional nature of the data used 
to establish the low-risk limits. The Quinte Longitudinal 
Study (QLS) followed a cohort of over 4,000 Ontarians 
over 5 years. The randomly selected sample (mean age 
= 46 years; 55% female) was composed of individuals 
with a range of gambling habits and problem gambling 
characteristics. In preliminary analysis of the predictors 
of future gambling problems, measures of gambling 
intensity at baseline were found to be highly associ-
ated with the onset of problem gambling at subsequent 
time periods. We extend this work by adapting the risk-
curve approach used in the development of the low-risk 
gambling limits to the QLS longitudinal data. Using a 
combination of ROC analysis, risk-curves and regression 
analyses we identified the optional cut-offs for predict-
ing future harm from gambling based on measures of 
gambling intensity (frequency, total expenditure, and 
percent of household income spent on gambling). The 
limits will be cross-validated with another longitudi-
nal data set the Leisure, Lifestyle, Lifecycle Project, 
an Alberta based study of over 1800 for five years. The 
findings of this work and their implications for problem 
gambling prevention activities will be presented. 
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